

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10859 A1

(51) International Patent Classification⁷: C07D 401/12,
401/06, 401/14, 417/14, A61K 31/50, A61P 9/14

Stephen, James; 233 Colony Street, Fairfield, CT 06430
(US).

(21) International Application Number: PCT/US00/21579

(74) Agents: GREENMAN, Jeffrey, M. et al.: Bayer Corporation,
400 Morgan Lane, West Haven, CT 06516 (US).

(22) International Filing Date: 8 August 2000 (08.08.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

(30) Priority Data:
09/371,322 10 August 1999 (10.08.1999) US


- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(71) Applicant: BAYER CORPORATION [US/US]; 100
Bayer Road, Pittsburgh, PA 15205 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: DUMAS, Jacques, P.; 821 Beechwood
Road, Orange, CT 06477 (US). HATOUM-MOKDAD,
Holia, N.; 43 Joseph Lane, Hamden, CT 06514 (US).
JOE, Teddy, Kite; 516 East 80th Street, Apt. 6, New
York, NY 10021 (US). KLUENDER, Harold, C., E.;
27 Academy Road, Trumbull, CT 06611 (US). LEE,
Wendy; 282 Evergreen Avenue, Hamden, CT 06518 (US).
NAGARATHNAM, Dhanapalan; 52 Virginia Rail Drive,
Bethany, CT 06524 (US). SIBLEY, Robert, N.; 1187
Mount Carmel Avenue, North Haven, CT 06473 (US). SU,
Ning; 16 Earle Street, Milford, CT 06460 (US). BOYER,

(54) Title: SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY



(57) Abstract: Substituted and fused pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R¹ and R² may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

Substituted Pyridazines and Fused Pyridazines with Angiogenesis Inhibiting Activity**FIELD:**

5 This application relates to small molecule heterocyclic pharmaceuticals, and more particularly, to substituted and fused pyridazines having angiogenesis inhibiting activity.

BACKGROUND:

10 Vasculogenesis involves the *de novo* formation of blood vessels from endothelial cell precursors or angioblasts. The first vascular structures in the embryo are formed by vasculogenesis. Angiogenesis involves the development of capillaries from existing blood vessels, and is the principle mechanism by which organs, such as the brain and the kidney are vascularized. While vasculogenesis is restricted to embryonic development, angiogenesis can occur in the adult, for example during pregnancy, the female cycle, or 15 wound healing.

20 One major regulator of angiogenesis and vasculogenesis in both embryonic development and some angiogenic-dependent diseases is vascular endothelial growth factor (VEGF; also called vascular permeability factor, VPF). VEGF represents a family of mitogens isoforms resulting from alternative mRNA splicing and which exist in homodimeric forms. The VEGF KDR receptor is highly specific for vascular endothelial cells (for reviews, see: Farrara et al. *Endocr. Rev.* 1992, 13, 18; Neufeld et al. *FASEB J.* 1999, 13, 9).

25 VEGF expression is induced by hypoxia (Shweiki et al. *Nature* 1992, 359, 843), as well as by a variety of cytokines and growth factors, such as interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- α and - β .

To date VEGF and the VEGF family members have been reported to bind to one or more of three transmembrane receptor tyrosine kinases (Mustonen et al. *J. Cell Biol.*, 1995, 129, 895), VEGF receptor-1 (also known as flt-1 (fms-like tyrosine kinase-1)); VEGFR-2 (also known as kinase insert domain containing receptor (KDR), the murine 30 analogue of KDR being known as fetal liver kinase-1 (flk-1)); and VEGFR-3 (also known as flt-4). KDR and flt-1 have been shown to have different signal transduction properties (Waltenberger et al. *J. Biol. Chem.* 1994, 269, 26988); Park et al. *Oncogene* 1995, 10, 135). Thus, KDR undergoes strong ligand-dependent tyrosine phosphorylation in intact

cells, whereas flt-1 displays a weaker response. Thus, binding to KDR is a critical requirement for induction of the full spectrum of VEGF-mediated biological responses.

5 *In vivo*, VEGF plays a central role in vasculogenesis, and induces angiogenesis and permeabilization of blood vessels. Deregulated VEGF expression contributes to the development of a number of diseases that are characterized by abnormal angiogenesis and/or hyperpermeability processes. Regulation of the VEGF-mediated signal transduction cascade will therefore provide a useful mode for control of abnormal angiogenesis and/or hyperpermeability processes.

10 Angiogenesis is regarded as an absolute prerequisite for growth of tumors beyond about 1-2 mm. Oxygen and nutrients may be supplied to cells in tumors smaller than this limit through diffusion. However, every tumor is dependent on angiogenesis for continued growth after it has reached a certain size. Tumorigenic cells within hypoxic regions of tumors respond by stimulation of VEGF production, which triggers activation of quiescent endothelial cells to stimulate new blood vessel formation. (Shweiki et al. 15 *Proc. Nat'l. Acad. Sci.*, 1995, 92, 768). In addition, VEGF production in tumor regions where there is no angiogenesis may proceed through the ras signal transduction pathway (Grugel et al. *J. Biol. Chem.*, 1995, 270, 25915; Rak et al. *Cancer Res.* 1995, 55, 4575). In situ hybridization studies have demonstrated VEGF mRNA is strongly upregulated in a wide variety of human tumors, including lung (Mattern et al. *Br. J. Cancer* 1996, 73, 931), 20 thyroid (Viglietto et al. *Oncogene* 1995, 11, 1569), breast (Brown et al. *Human Pathol.* 1995, 26, 86), gastrointestinal tract (Brown et al. *Cancer Res.* 1993, 53, 4727; Suzuki et al. *Cancer Res.* 1996, 56, 3004), kidney and bladder (Brown et al. *Am. J. Pathol.* 1993, 143I, 1255), ovary (Olson et al. *Cancer Res.* 1994, 54, 1255), and cervical (Guidi et al. *J. Nat'l Cancer Inst.* 1995, 87, 12137) carcinomas, as well as angiosarcoma (Hashimoto et 25 al. *Lab. Invest.* 1995, 73, 859) and several intracranial tumors (Plate et al. *Nature* 1992, 359, 845; Phillips et al. *Int. J. Oncol.* 1993, 2, 913; Berkman et al. *J. Clin. Invest.*, 1993, 91, 153). Neutralizing monoclonal antibodies to KDR have been shown to be efficacious in blocking tumor angiogenesis (Kim et al. *Nature* 1993, 362, 841; Rockwell et al. *Mol. Cell. Differ.* 1995, 3, 315).

30 Overexpression of VEGF, for example under conditions of extreme hypoxia, can lead to intraocular angiogenesis, resulting in hyperproliferation of blood vessels, leading eventually to blindness. Such a cascade of events has been observed for a number of retinopathies, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity (Aiello et al. *New Engl. J. Med.* 1994, 331, 1480; Peer et al. *Lab. Invest.*

1995, 72, 638), and age-related macular degeneration (AMD; see, Lopez et al. *Invest. Ophthalmol. Vis. Sci.* 1996, 37, 855).

5 In rheumatoid arthritis (RA), the in-growth of vascular pannus may be mediated by production of angiogenic factors. Levels of immunoreactive VEGF are high in the synovial fluid of RA patients, while VEGF levels were low in the synovial fluid of patients with other forms of arthritis or with degenerative joint disease (Koch et al. *J. Immunol.* 1994, 152, 4149). The angiogenesis inhibitor AGM-170 has been shown to prevent neovascularization of the joint in the rat collagen arthritis model (Peacock et al. *J. Exper. Med.* 1992, 175, 1135).

10 Increased VEGF expression has also been shown in psoriatic skin, as well as bullous disorders associated with subepidermal blister formation, such as bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis (Brown et al. *J. Invest. Dermatol.* 1995, 104, 744).

15 Because inhibition of KDR signal transduction leads to inhibition of VEGF-mediated angiogenesis and permeabilization, KDR inhibitors will be useful in treatment of diseases characterized by abnormal angiogenesis and/or hyperpermeability processes, including the above listed diseases

20 Examples of phthalazines and other fused pyridazines that are similar in structure to those of the present application are disclosed in the following patents or patent applications: WO 9835958 (Novartis), US 5,849,741, US 3,753,988, US 3,478,028 and JP 03106875. Other literature references to phthalazines are El-Feky, S.A., Bayoumy, B.E., and Abd El-Sami, Z.K., Egypt. J. Chem. (1991), Volume Date 1990, 33(2), 189-197; Duhault, J., Gonnard, P., and Fenard, S., Bull. Soc. Chim. Biol., (1967), 49 (2), 177-190; and Holava, H.M. and Jr, Partyka, R.A., J. Med. Chem., (1969), 12, 555-556. The 25 compounds of the present invention are distinct from those described in each of the above references, and only the Novartis publication describes such compounds as inhibitors of angiogenesis.


30 As explained above, compounds which inhibit angiogenesis have applicability in treatment of a variety of medical conditions, and are therefore desirable. Such materials are the subject of the present application.

SUMMARY:

In its broadest aspect, the present invention relates to the sum of three sets of chemical compounds, or pharmaceutically acceptable salts or prodrugs thereof, with each

set overlapping the others in scope. The generalized structural formula for the compounds in each of the three sets of compounds is the same, but it should be noted that the definitions of the several groups comprising the general structure in each set differ somewhat. Thus, the defined sets of chemical compounds differ from each other, but 5 overlap in their scopes.


The first set of compounds have the generalized structural formula



wherein


R^1 and R^2 :

10 i) independently represent H or lower alkyl;
ii) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms;


iii) together form a bridge of structure



15

wherein binding is achieved via the terminal carbon atoms; or

iv) together form a bridge of structure



20

wherein one or two ring members T^1 are N and the others are CH, and binding is achieved via the terminal atoms.

In the above bridge substructures, the subscript m is 0 or an integer 1 - 4, indicating that the resultant fused rings may optionally bear up to four substituents G^1 .

G^1 is a substituent independently selected from the group consisting of: $-N(R^6)_2$; $-NR^3COR^6$; halogen; alkyl; cycloalkyl; lower alkenyl; lower cycloalkenyl; halogen-substituted alkyl; amino-substituted alkyl; N-lower alkylamino-substituted alkyl; N,N-di-lower alkylamino-substituted alkyl; N-lower alkanoylamino-substituted alkyl; hydroxy-

substituted alkyl; cyano-substituted alkyl; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; phenyl lower alkoxy carbonyl-substituted alkyl; halogen-substituted alkylamino; amino-substituted alkylamino; N-lower alkylamino-substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower 5 alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; cyano-substituted alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; phenyl-lower alkoxy carbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower 10 alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -CH₂OR³; -NO₂; -CN; amidino; guanidino; sulfo; -B(OH)₂; optionally substituted aryl; optionally substituted heteroaryl; 15 optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; -OCO₂R³; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -CHO; -OCON(R⁶)₂; -NR³CO₂R⁶; and -NR³CON(R⁶)₂.

The group R³ is H or lower alkyl. R⁶ is independently selected from the group consisting of H; alkyl; optionally substituted aryl; and optionally substituted aryl lower alkyl.

In generalized structural formula (I), R⁴ is H, halogen, or lower alkyl; the subscript 20 p is 0, 1, or 2; and X is selected from the group consisting of O, S, and NH.

The linking moiety Y is selected from the group consisting of: -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s; -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s; -O-CH₂-; -S(O)-; -S(O)₂-; -SCH₂-; -S(O)CH₂-; -S(O)₂CH₂-; -CH₂S(O)-; and -CH₂S(O)₂- . In the first two members of the above list of possible Y groups, the subscripts n and s are each 25 independently 0 or an integer of 1 - 2. The substituent G² is selected from the group consisting of -CN; -CO₂R³; -CON(R⁶)₂; and -CH₂N(R⁶)₂ .

In the ring shown at the left in generalized structural formula (I), A and D independently represent N or CH; B and E independently represent N or CH; and L represents N or CH; with the provisos that a) the total number of N atoms in the ring 30 containing A, B, D, E, and L is 1, 2, or 3; and b) when L represents CH, at least one of A and D is an N atom. The subscript q, which indicates the number of possible substituents G³ on the ring, is 0, 1, or 2. Substituent moieties G³ are selected from the group consisting of lower alkyl; -NR³COR⁶; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; -OCOR⁶; -COR⁶; -CO₂R⁶; -CH₂OR³;

-CON(R⁶)₂; -S(O)₂N(R⁶)₂; -NO₂; -CN; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -OCON(R⁶)₂; -NR³CO₂R⁶; and -NR³CON(R⁶)₂.

5 J is a ring selected from the group consisting of aryl; pyridyl; and cycloalkyl. The subscript q' represents the number of substituents G⁴ on ring J and is 0, 1, 2, 3, 4, or 5.

The possible substituents G⁴ on ring J are selected from the group consisting of

10 -N(R⁶)₂; -NR³COR⁶; halogen; alkyl; cycloalkyl; lower alkenyl; lower cycloalkenyl; halogen-substituted alkyl; amino-substituted alkyl; N-lower alkylamino-substituted alkyl; N,N-di-lower alkylamino-substituted alkyl; N-lower alkanoylamino-substituted alkyl; hydroxy-substituted alkyl; cyano-substituted alkyl; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; phenyl lower alkoxy carbonyl-substituted alkyl;


15 halogen-substituted alkylamino; amino-substituted alkylamino; N-lower alkylamino-substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; cyano-substituted alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; phenyl-lower alkoxy carbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶;

20 -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -CH₂OR³; -NO₂; -CN; amidino; guanidino; sulfo; -B(OH)₂; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; -OCO₂R³; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -CHO; -OCON(R⁶)₂; -NR³CO₂R⁶; -NR³CON(R⁶)₂; as well as

25


fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

30 a)



wherein each T^2 independently represents N, CH, or CG^4 ; T^3 represents S, O, CR^4G^4 , $C(R^4)_2$, or NR^3 ; and binding to ring J is achieved via terminal atoms T^2 and T^3 ;


b)



5

wherein each T^2 independently represents N, CH, or CG^4 ; with the proviso that a maximum of two bridge atoms T^2 may be N; and binding to ring J is achieved via terminal atoms T^2 ; and

c)



10

wherein each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $C(R^4)_2$, or NR^3 ; and binding to ring J is achieved via terminal atoms T^4 or T^5 ; with the provisos that:

15

- when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;
- a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom.


20

Additional provisos are that, 1) in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and 2) when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CHO$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano.

25

30


The second set of compounds have the generalized structural formula



wherein

5 R¹ and R²:

- i) independently represent H or lower alkyl;
- ii) together form a bridge of structure




wherein binding is achieved via the terminal carbon atoms;

10 iii) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms; or

iv) together form a bridge of structure



15 wherein one or two ring members T¹ are N and the others are CH, and binding is achieved via the terminal atoms:

In the above bridge substructures, the subscript m is 0 or an integer 1 - 4; indicating that the resultant fused rings may optionally bear up to four substituents G¹.

19 G¹ is a substituent independently selected from the group consisting of: -N(R⁶)₂ ;
 20 -NR³COR⁶ ; halogen; alkyl; cycloalkyl; lower alkenyl; lower cycloalkenyl; halogen-
 substituted alkyl; amino-substituted alkyl; N-lower alkylamino-substituted alkyl; N,N-di-
 lower alkylamino-substituted alkyl; N-lower alkanoylamino-substituted alkyl; hydroxy-
 substituted alkyl; cyano-substituted alkyl; carboxy-substituted alkyl; lower
 alkoxycarbonyl-substituted alkyl; phenyl lower alkoxycarbonyl-substituted alkyl;
 25 halogen-substituted alkylamino; amino-substituted alkylamino; N-lower alkylamino-
 substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower

alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; cyano-substituted alkylamino; carboxy-substituted alkylamino; lower alkoxycarbonyl-substituted alkylamino; phenyl-lower alkoxycarbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -CH₂OR³; -NO₂; -CN; amidino; guanidino; sulfo; -B(OH)₂; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocyclyl; optionally substituted partially unsaturated heterocyclyl; -OCO₂R³; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -CHO; -OCON(R⁶)₂; -NR³CO₂R⁶; and -NR³CON(R⁶)₂.

The group R³ is H or lower alkyl. R⁶ is independently selected from the group consisting of H; alkyl; optionally substituted aryl; and optionally substituted aryl lower alkyl.

15 In generalized structural formula (I), R⁴ is H, halogen, or lower alkyl; the subscript p is 0, 1, or 2; and X is selected from the group consisting of O, S, and NH.

The linking moiety Y is selected from the group consisting of: lower alkylene, optionally substituted by OH or OAcyl; -CH₂-O-; -CH₂-S-; -CH₂-NH-; -O-; -S-; -NH-; -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s; -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s-; -O-CH₂-; -S(O)-; -S(O)₂-; -SCH₂-; -S(O)CH₂-; -S(O)₂CH₂-; -CH₂S(O)-; and -CH₂S(O)₂-.

20 In the eighth and ninth members of the above list of possible Y groups, the subscripts n and s are each independently 0 or an integer of 1 - 2. The substituent G² is selected from the group consisting of -CN; -CO₂R³; -CON(R⁶)₂; and -CH₂N(R⁶)₂.

25 In the ring shown at the left in generalized structural formula (I), A and D independently represent N or CH; B and E independently represent N or CH; and L represents N or CH; with the provisos that a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and b) when L represents CH, at least one of A and D is an N atom. The subscript q, which indicates the number of possible substituents G³ on the ring, is 0, 1, or 2. Substituent moieties G³ are selected from the group 30 consisting of -NR³COR⁶; carboxy-substituted alkyl; lower alkoxycarbonyl-substituted alkyl; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; -OCOR⁶; -COR⁶; -CO₂R⁶; -CH₂OR³; -CON(R⁶)₂; -S(O)₂N(R⁶)₂; -NO₂; -CN; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocyclyl; optionally substituted partially unsaturated heterocyclyl; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy;


-S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -OCON(R⁶)₂; -NR³CO₂R⁶; and -NR³CON(R⁶)₂.

5 J is a ring selected from the group consisting of aryl; pyridyl; and cycloalkyl. The subscript q' represents the number of substituents G⁴ on ring J and is 0, 1, 2, 3, 4, or 5.

The possible substituents G⁴ on ring J are selected from the group consisting of -N(R⁶)₂; -NR³COR⁶; halogen; alkyl; cycloalkyl; lower alkenyl; lower cycloalkenyl; halogen-substituted alkyl; amino-substituted alkyl; N-lower alkylamino-substituted alkyl; N,N-di-lower alkylamino-substituted alkyl; N-lower alkanoylamino-substituted alkyl; 10 hydroxy-substituted alkyl; cyano-substituted alkyl; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; phenyl lower alkoxy carbonyl-substituted alkyl; halogen-substituted alkylamino; amino-substituted alkylamino; N-lower alkylamino-substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; cyano-substituted 15 alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; phenyl-lower alkoxy carbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -CH₂OR³; -NO₂; -CN; amidino; guanidino; sulfo; -B(OH)₂; optionally substituted aryl; optionally substituted heteroaryl; 20 optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; -OCO₂R³; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -CHO; -OCON(R⁶)₂; -NR³CO₂R⁶; -NR³CON(R⁶)₂; as well as


25 fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)



wherein each T² independently represents N, CH, or CG⁴; T³ represents S, O, CR⁴G⁴, C(R⁴)₂, or NR³; and binding to ring J is achieved via terminal atoms T² and T³;


b)



5

wherein each T^2 independently represents N, CH, or CG^4 ; with the proviso that a maximum of two bridge atoms T^2 may be N; and binding to ring J is achieved via terminal atoms T^2 ; and

c)



10

wherein each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $C(R^4)_2$, or NR^3 ; and binding to ring J is achieved via terminal atoms T^4 or T^5 ; with the provisos that:

15


- i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;
- ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom.

20

25

Additional provisos are that, 1) in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and 2) when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CHO$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano.


The third set of compounds have the generalized structural formula



wherein

R¹ and R² :


5 i) independently represent H or lower alkyl;
 ii) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms;
 iii) together form a bridge of structure



10 wherein binding is achieved via the terminal carbon atoms; or
 iv) together form a bridge of structure



15 wherein one or two ring members T¹ are N and the others are CH, and binding is
 achieved via the terminal atoms.

In the above bridge substructures, the subscript m is 0 or an integer 1 - 4;
 indicating that the resultant fused rings may optionally bear up to four substituents G¹.

20 G¹ is a substituent independently selected from the group consisting of: -N(R⁶)₂ ;
 -NR³COR⁶ ; halogen; alkyl; cycloalkyl; lower alkenyl; lower cycloalkenyl; halogen-
 substituted alkyl; amino-substituted alkyl; N-lower alkylamino-substituted alkyl; N,N-di-
 lower alkylamino-substituted alkyl; N-lower alkanoylamino-substituted alkyl; hydroxy-
 substituted alkyl; cyano-substituted alkyl; carboxy-substituted alkyl; lower
 alkoxy carbonyl-substituted alkyl; phenyl lower alkoxy carbonyl-substituted alkyl;
 halogen-substituted alkylamino; amino-substituted alkylamino; N-lower alkylamino-
 25 substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower
 alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; cyano-substituted

alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; phenyl-lower alkoxy carbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -CH₂OR³; -NO₂; -CN; amidino; 5 guanidino; sulfo; -B(OH)₂; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; -OCO₂R³; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; -S(O)_p(optionally substituted heteroarylalkyl); -CHO; -OCON(R⁶)₂; 10 -NR³CO₂R⁶; and -NR³CON(R⁶)₂.

The group R³ is H or lower alkyl. R⁶ is independently selected from the group consisting of H; alkyl; optionally substituted aryl; optionally substituted aryl lower alkyl.

In generalized structural formula (I), R⁴ is H, halogen, or lower alkyl; the subscript p is 0, 1, or 2; and X is selected from the group consisting of O, S, and NH.

15 The linking moiety Y is selected from the group consisting of lower alkylene, optionally substituted by OH or OAcyl; -CH₂-O-; -CH₂-S-; -CH₂-NH-; -O-; -S-; -NH-; -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s; -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s; -O-CH₂-; -S(O)-; -S(O)₂-; -SCH₂-; -S(O)CH₂-; -S(O)₂CH₂-; -CH₂S(O)-; and -CH₂S(O)₂-.

20 In the eighth and ninth members of the above list of possible Y groups, the subscripts n and s are each independently 0 or an integer of 1 - 2. The substituent G² is selected from the group consisting of -CN; -CO₂R³; -CON(R⁶)₂; and -CH₂N(R⁶)₂.

25 In the ring shown at the left in generalized structural formula (I), A and D independently represent N or CH; B and E independently represent N or CH; and L represents N or CH; with the provisos that a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and b) when L represents CH, at least one of A and D is an N atom. The subscript q, which indicates the number of possible substituents G³ on the ring, is 0, 1, or 2. Substituent moieties G³ are selected from the group consisting of lower alkyl; -NR³COR⁶; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; -OCOR⁶; -COR⁶; -CO₂R⁶; -CH₂OR³; 30 -CON(R⁶)₂; -S(O)₂N(R⁶)₂; -NO₂; -CN; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted saturated heterocycl; optionally substituted partially unsaturated heterocycl; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted


heteroarylalkyloxy; $-S(O)_p$ (optionally substituted heteroarylalkyl); $-OCON(R^6)_2$; $-NR^3CO_2R^6$; and $-NR^3CON(R^6)_2$.

J is a ring selected from the group consisting of aryl; pyridyl; and cycloalkyl. The subscript q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5.

5 The possible substituents G^4 on ring J are selected from the group consisting of optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; $-S(O)_p$ (optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; $-S(O)_p$ (optionally substituted heteroarylalkyl); $-CHO$; $-OCON(R^6)_2$; $-NR^3CO_2R^6$; $-NR^3CON(R^6)_2$; as well as


10 fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)




wherein each T^2 independently represents N, CH, or CG^4 ; T^3 represents S, O, CR^4G^4 , $C(R^4)_2$, or NR^3 ; and binding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)



20 wherein each T^2 independently represents N, CH, or CG^4 ; with the proviso that a maximum of two bridge atoms T^2 may be N ; and binding to ring J is achieved via terminal atoms T^2 ; and

c)



25 wherein each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $C(R^4)_2$, or NR^3 ; and binding to ring J is achieved via terminal atoms T^4 or T^5 ; with the provisos that:

- when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;
- a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 is O, the other T^5 is S, CR^4G^4 , $C(R^4)_2$ or NR^3 ;

iv) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom.

5

Additional provisos are that, 1) in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and 2) when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CHO$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, 10 guanidino, mercapto, sulfo, and cyano.

10

15

Pharmaceutically acceptable salts of these compounds as well as commonly used prodrugs of these compounds such as O-acyl derivatives of invention compounds which contain hydroxy groups are also within the scope of the invention.

20

The invention also relates to pharmaceutical compositions comprising one or more of the compounds of the invention, or their salts or prodrugs, in a pharmaceutically acceptable carrier.

25

The invention also relates to a method for using these materials to treat a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to the mammal an amount of a compound of the invention, or a salt or prodrug thereof, which is effective to treat the condition.

DETAILED DESCRIPTION:

Definitions:

30

The prefix "lower" denotes a radical having up to and including a maximum of 7 atoms, especially up to and including a maximum of 5 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.

“Alkyl” means a hydrocarbon radical having up to a maximum of 12 carbon atoms, which may be linear or branched with single or multiple branching. Alkyl is especially lower alkyl.

Where the plural form is used for compounds, salts, and the like, this is taken to 5 mean also a single compound, salt, or the like.

Any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)configuration, preferably in the (R)- or (S)-configuration. Substituents at a double bond or a ring may be present in cis- (= Z-) or trans (= E-) form. The compounds may thus be present as mixtures of isomers or as pure isomers, preferably as enantiomer-pure 10 diastereomers and having pure cis- or trans- double bonds.

Lower alkylene Y may be branched or linear but is preferably linear, especially methylene (-CH₂), ethylene (-CH₂-CH₂), trimethylene (-CH₂-CH₂-CH₂) or tetramethylene (-CH₂CH₂CH₂CH₂). When Y is lower alkylene, it is most preferably methylene.

“Aryl” means an aromatic radical having 6 to 14 carbon atoms, such as phenyl, 15 naphthyl, fluorenyl or phenanthrenyl.

“Halogen” means fluorine, chlorine, bromine, or iodine but is especially fluorine, chlorine, or bromine.

“Pyridyl” means 1-, 2-, or 3-pyridyl but is especially 2- or 3-pyridyl.

“Cycloalkyl” is a saturated carbocycle that contains between 3 and 12 carbons but 20 preferably 3 to 8 carbons.


“Cycloalkenyl” means a non-reactive and non-aromatic unsaturated carbocycle that contains between 3 and 12 carbons but preferably 3 to 8 carbons and up to three double bonds. It is well known to those skilled in the art that cycloalkenyl groups that differ from aromatics by lacking only one double bond such as cyclohexadiene are not 25 sufficiently non-reactive to be reasonable drug substances and therefore their use as substituents is not within the scope of this invention.

Cycloalkyl and cycloalkenyl groups may contain branch points such that they are substituted by alkyl or alkenyl groups. Examples of such branched cyclic groups are 3,4-dimethylcyclopentyl, 4-allylcyclohexyl or 3-ethylcyclopent-3-enyl.


30 Salts are especially the pharmaceutically acceptable salts of compounds of formula I such as, for example, acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom. Suitable inorganic acids are, for example, halogen acids such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic, or sulfamic

acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, -hydroxybutyric acid, gluconic acid, glucosemonocarboxylic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azeiaic acid, malic acid, tartaric acid, citric acid, glucaric acid, galactaric acid, amino acids, such as glutamic acid, aspartic acid, N-methylglycine, acetytarninoacetic acid, N-acetylasparagine or N-acetylcysteine, pyruvic acid, acetoacetic acid, phosphoserine, 2- or 3-glycerophosphoric acid.

In the definition of Y, the diradical “-(5 member heteraryl)-” denotes a 5-membered aromatic heterocycle containing 1-3 heteroatoms selected from O, S, and N, the number of N atoms being 0-3 and the number of O and S atoms each being 0-1 and connected to the sulfur from a carbon and to $-(CR^4_2)_s-$ through a C or N atom. Examples of such diradicals include



In the definitions of G^1 , G^2 , G^3 , and G^4 the statement is made that when two groups R^6 are found on a single N, they can be combined into a heterocycle of 5-7 atoms. Examples of such heterocycles, including the N to which they are attached, are:




“Heterocycl” or “heterocycle” means a five- to seven-membered heterocyclic system with 1-3 heteroatoms selected from the group nitrogen, oxygen, and sulfur, which may be unsaturated or wholly or partly saturated, and is unsubstituted or substituted especially by lower alkyl, such as methyl, ethyl, 1-propyl, 2-propyl, or tert-butyl.

When an aryl, heteraryl, or heterocycl ring is said to be optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono- or di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl such as trifluoromethyl, hydroxy, lower 5 alkoxy, lower alkylthio, halogenated lower alkoxy such as trifluoromethoxy, halogenated lower alkylthio such as trifluoromethylthio, lower alkanoyloxy, $-\text{CO}_2\text{R}^3$, $-\text{CHO}$, $-\text{CH}_2\text{OR}^3$, $-\text{OCO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, $-\text{OCO}_2\text{N}(\text{R}^6)_2$, $-\text{NR}^3\text{CON}(\text{R}^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano.

In the ring attached to Y, the ring members A, B, D, E, and L may be N or CH, it 10 being understood that the optional substituents G^3 are necessarily attached to carbon and not nitrogen, and that when a given carbon bears a substituent group G^3 , that G^3 group is in place of the H atom the carbon would bear in the absence of the G^3 group.

Examples of ring J together with two adjacent G^4 moieties which taken together form a second fused ring are:



15


“Heteraryl” means a monocyclic or fused bicyclic aromatic system with between 5 and 10 atoms in total of which 1-4 are heteroatoms selected from the group comprising nitrogen, oxygen, and sulfur and with the remainder being carbon. Heteraryl is preferably a monocyclic system with 5 or 6 atoms in total, of which 1-3 are heteroatoms.

"Alkenyl" means an unsaturated radical having up to a maximum of 12 carbon atoms and may be linear or branched with single or multiple branching and containing up to 3 double bonds. Alkenyl is especially lower alkenyl with up to 2 double bonds.


"Alkanoyl" means alkylcarbonyl, and is especially lower alkylcarbonyl.

5 Halogenated lower alkyl, halogenated lower alkoxy and halogenated lower alkylthio are substituents in which the alkyl moieties are substituted either partially or in full with halogens, preferably with chlorine and/or fluorine and most preferably with fluorine. Examples of such substituents are trifluoromethyl, trifluoromethoxy, trifluoromethylthio, 1,1,2,2-tetrafluoroethoxy, dichloromethyl, fluoromethyl and 10 difluoromethyl.

When a substituent is named as a string of fragments such as "phenyl-lower alkoxy carbonyl-substituted alkylamino," it is understood that the point of attachment is to the final moiety of that string (in this case amino) and that the other fragments of that string are connected to each other in sequence as they are listed in the string. Thus an 15 example of "phenyl-lower alkoxy carbonyl-substituted alkylamino" is:




When a substituent is named as a string of fragments with a bond at the start (typically written as a dash) such as "-S(O)_p(optionally substituted heteroarylalkyl)", it is understood that the point of attachment is to the first atom of that string (in this case S or 20 sulfur) and that the other fragments of that string are connected to each other in sequence as they are listed in the string. Thus an example of "-S(O)_p(optionally substituted heteroarylalkyl)" is:



It is to be understood that the left-most moiety of each of the variants of the linker 25 Y is connected to the ring containing A, B, D, E, and L and that the right-most moiety of the linker is connected to the pyridazine fragment of the generalized formulae. Thus

examples of the use of the linker “-CH₂-O-“ or of the linker “-O-CH₂-“ are represented in the following invention compounds:




5 Preferred and most preferred groups:

In generalized structural formula (I), the preferred groups are as follows.


R¹ and R² preferably:

i) together form a bridge of structure



10 wherein binding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and binding is achieved via the terminal atoms.

15 Most preferably, any group G¹ is located on a non-terminal atom of the bridge.

The subscript m is preferably 0 or an integer 1 – 2, and substituents G¹ are preferably selected from the group consisting of -N(R⁶)₂; -NR³COR⁶; halogen; alkyl; amino-substituted alkylamino; N-lower alkylamino-substituted alkylamino; N,N-di-lower alkylamino-substituted alkylamino; N-lower alkanoylamino-substituted alkylamino;

20 hydroxy-substituted alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; -OR⁶; -SR⁶; -S(O)R⁶; -S(O)₂R⁶; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower alkylsulfonyl; -OCOR⁶; -COR⁶; -CO₂R⁶; -CON(R⁶)₂; -NO₂; -CN; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; -S(O)_p(optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; and -S(O)_p(optionally substituted heteroarylalkyl). Most preferably,

G^1 is a substituent independently selected from the group consisting of $-N(R^6)_2$; $-NR^3COR^6$; halogen; $-OR^6$ wherein R^6 represents lower alkyl; $-NO_2$; optionally substituted heteroaryloxy; and optionally substituted heteroarylalkyloxy.

When R^6 is an alkyl group, it is preferably lower alkyl. The group R^4 is preferably 5 H ; p is preferably 0 or 1; and X is preferably NH . In the linker group Y , the subscripts n and s are preferably 0, 1, or 2. Most preferably, Y is selected from the group consisting of lower alkylene, optionally substituted by OH ; $-CH_2-O-$; $-S-$; $-NH-$; $-S(O)_p$ -(5-membered heteroaryl)-; $-C(CN)(H)-$; $-O-CH_2-$; $-S(O)-$; and $-S(O)_2-$.

In the ring at the left side of the structure (I), B and E are preferably CH , and the 10 total number of N atoms in this ring is preferably 1 or 2. Most preferably, A , B , D , and E are each CH and L is an N atom, making this ring a pyridine.


The substituents G^3 are preferably selected from the group consisting of lower 15 alkyl; $-NR^3COR^6$; $-OR^6$; $-SR^6$; $-S(O)R^6$; $-S(O)_2R^6$; $-CO_2R^6$; $-CON(R^6)_2$; $-S(O)_2N(R^6)_2$; $-CN$; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; $-S(O)_p$ (optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; and $-S(O)_p$ (optionally substituted heteroarylalkyl). Most preferably, G^3 is selected from the group consisting of lower alkyl; $-NR^3COR^6$; $-CO_2R^6$; $-CON(R^6)_2$; and $-S(O)_2N(R^6)_2$. Most preferably, the subscript q , which represents the number of substituents G^3 , is 0 or 1.

20 Ring J is preferably a phenyl ring, and subscript q' representing the number of substituents G^4 on the phenyl ring, is preferably 0, 1, 2, or 3.

G^4 moieties are preferably selected from the group consisting of $-N(R^6)_2$; $-NR^3COR^6$; halogen; alkyl; halogen-substituted alkyl; hydroxy-substituted alkyl; carboxy-substituted alkyl; lower alkoxy carbonyl-substituted alkyl; amino-substituted 25 alkylamino; N -lower alkylamino-substituted alkylamino; N,N -di-lower alkylamino-substituted alkylamino; N -lower alkanoylamino-substituted alkylamino; hydroxy-substituted alkylamino; carboxy-substituted alkylamino; lower alkoxy carbonyl-substituted alkylamino; phenyl-lower alkoxy carbonyl-substituted alkylamino; $-OR^6$; $-SR^6$; $-S(O)R^6$; $-S(O)_2R^6$; halogenated lower alkoxy; halogenated lower alkylthio; halogenated lower 30 alkylsulfonyl; $-OCOR^6$; $-COR^6$; $-CO_2R^6$; $-CON(R^6)_2$; $-CH_2OR^3$; $-NO_2$; $-CN$; optionally substituted heteroarylalkyl; optionally substituted heteroaryloxy; $-S(O)_p$ (optionally substituted heteroaryl); optionally substituted heteroarylalkyloxy; $-S(O)_p$ (optionally substituted heteroarylalkyl); as well as


fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




5 wherein each T² independently represents N, CH, or CG⁴; T³ represents S, O, CHG⁴, CH₂, or NR³; and binding to the phenyl ring is achieved via terminal atoms T² and T³;

b)



10 wherein each T² independently represents N, CH, or CG⁴; with the proviso that a maximum of two bridge atoms T² may be N; and binding to the phenyl ring is achieved via terminal atoms T²; and

c)



15 wherein each T⁵ and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³; and binding to the phenyl ring is achieved via terminal atoms T⁵.

Most preferably, in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a N-containing heterocycle of 5 – 6 ring atoms.

20 Preferably, when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, and cyano.

25 Most preferably, when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-

substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, nitro, and cyano.

5 The method of the invention is intended to be employed for treatment of VEGF-mediated conditions in both humans and other mammals.

The compounds may be administered orally, dermally, parenterally, by injection, by inhalation or spray, or sublingually, rectally or vaginally in dosage unit formulations. The term 'administered by injection' includes intravenous, intraarticular, intramuscular, 10 subcutaneous and parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired, other active ingredients.

15 Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.

Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients 20 may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby 25 provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.

Formulations for oral use may also be presented as hard gelatin capsules wherein 30 the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose,

hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or *n*-propyl, *p*-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.

Compounds of the invention may also be administered transdermally using methods known to those skilled in the art (see, for example: Chien; "Transdermal Controlled Systemic Medications"; Marcel Dekker, Inc.; 1987. Lipp et al. WO 94/04157 3Mar94). For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.

Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluorøthane. Suitable solvents may also include mixtures one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.

Suitable penetration enhancing materials for transdermal delivery systems are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C₈-C₁₈ fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C₈-C₁₈ fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, *n*-butyl, *sec*-butyl isobutyl *tert*-butyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of

up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbit and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures 5 one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C₈-C₁₈ fatty alcohols, saturated or unsaturated C₈-C₁₈ fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated 10 dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.

Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrene-butadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. 15 Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.

For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous 20 and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times 25 daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg. The daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.

It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely 30 when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, but not limited to the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug


combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, ie., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be
5 ascertained by those skilled in the art using conventional treatment tests.

GENERAL PREPARATIVE METHODS:

10 The compounds of the invention may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aid the reader in synthesizing the KDR inhibitors, with more detailed particular examples being presented below in the experimental section describing the working examples. Reference Compound A was prepared by the methods described in Novartis WO 9835958.


15 All variable groups of these methods are as described in the generic description if they are not specifically defined below. When a variable group or substituent with a given symbol (i.e. R³, R⁴, R⁶, G¹, G², G³, or G⁴) is used more than once in a given structure, it is to be understood that each of these groups or substituents may be independently varied within the range of definitions for that symbol. As defined above, the compounds of the
20 invention contain ring units each of which may independently bear between 0 and 5 substituents G¹, G³, or G⁴ which are not defined as H. By contrast, it is to be noted that in the general method schemes below, the G¹, G³, or G⁴ substituents are used as if their definition includes H, to show where such G¹, G³, or G⁴ substituents may exist in the structures, and for ease in drawing. No change in the definition of G¹, G³, or G⁴ is
25 intended by this non-standard usage, however. Thus, only for purposes of the general method schemes below, G¹, G³, or G⁴ may be H in addition to the moieties set forth in the definitions of G¹, G³, or G⁴. The ultimate compounds contain 0 to 5 non-hydrogen groups G¹, G³, or G⁴.

Within these general methods the variable M is equivalent to the moiety




30 in which each variable group or substituent is allowed to independently vary within the limits defined earlier for that symbol.

Within these general methods the variable Q^1 is equivalent to the moiety



in which L is N and each other variable group or substituent is allowed to independently vary within the limits defined earlier for that symbol.

Within these general methods the variable Q^2 is equivalent to the moiety




5 in which each variable group or substituent is allowed to independently vary within the limits defined earlier for that symbol.

It is recognized that compounds of the invention with each claimed optional functional group cannot be prepared with each of the below-listed methods. Within the scope of each method optional substituents are used which are stable to the reaction 10 conditions, or the functional groups which may participate in the reactions are present in protected form where necessary, and the removal of such protective groups is completed at appropriate stages by methods well known to those skilled in the art.

15 General Method A - The compounds of formula I-D-1 in which R^1 , R^2 , R^6 , M, X and Y are defined as above are conveniently prepared via a reaction sequence as shown in Method A. Thus, readily prepared substituted fused or unfused pyridazines (I-D) (as described in Novartis application WO 98 35958) are functionalized into substituted 2-aminocarbonyl pyridines of formula (I-D-1) by the use of formamides (II) in the presence 20 of hydrogen peroxide and iron salts, according to a procedure described in the literature (Minisci et al., *Tetrahedron*, 1985, 41, 4157).


Method A



25 General Method B - The compounds of formula I-D-2 in which R^1 , R^2 , R^6 , M, X and Y are defined as above and R^3 is lower alkyl are conveniently prepared via a reaction sequence as shown in Method B. Thus, readily prepared substituted fused or unfused


pyridazines (I-D) (as described in Novartis application WO 98 35958) are functionalized into substituted 2-alkoxycarbonyl pyridines of formula (I-D-2) by the use of monoalkyloxalates (III) in the presence of $S_2O_8^{2-}$, acid and catalytic amounts of $AgNO_3$, according to a procedure described in the literature (Coppa, F. et al., *Tetrahedron Letters*, 5 1992, 33 (21), 3057). Compounds of formula I-D-2 in which R^3 is H are then formed by hydrolysis of the ester with a base such as sodium hydroxide in methanol / water. Compounds of formula I-D-3 in which the R^6 groups are independently defined as above, but especially including those compounds in which neither R^6 is H, are conveniently prepared from the acid (I-D-2, R^3 = H) by treatment with amine IV in the presence of a 10 coupling agent such as DCC (dicyclohexylcarbodiimide).

Method B



15 **General Method C** - The compounds of formula I-D-4 in which M, X, R^1 , R^2 , and Q^1 are defined as above are conveniently prepared according to a reaction sequence as shown in Method C. Thus, a substituted keto acid having structure V, in which R^1 and R^2 together with the carbons to which they are attached are a fused optionally substituted phenyl or fused 6-member heterocycle is reacted with potassium permanganate according 20 to the procedure of Hatam, N. A. R.; Whiting, D. A. *J. Chem Soc. C* 1969 1921. Compounds of formula VI in which R^1 and R^2 are lower alkyl are conveniently prepared according to procedures given in patent CH 482415 (Chem. Abstr. 120261u, 1970). The crude diacid of formula VI is subsequently treated with hydrazine to furnish pyridazinone VII (for specific reaction conditions see Vaughn, W. R.; Baird, S. L. *J. Am. Chem. Soc.* 25 1946 68 1314). Pyridazinone VII is treated with a chlorinating agent such as phosphorous oxychloride to yield an intermediate dichloro species which undergoes hydrolysis upon aqueous workup to furnish chloropyridazine VIII. Chloro acid VIII is treated with a nucleophile of formula IX in the presence of a base such as sodium hydride. The resultant acid X is reduced with a reducing agent such as $BH_3 \bullet THF$ according to the procedure of 30 Tilley, J. W.; Coffen D. L. Schaefer, B. H.; Lind, J. *J. Org. Chem.* 1987 52 2469. Product


alcohol XI is reacted with a base and optionally substituted 4-halo-pridyl, optionally substituted 4-halo-pyrimidyl or optionally substituted 4-halo-pyridazyl (XII) to furnish invention compound of formula I-D-4 (for specific reaction conditions see Barlow, J. J.; Block, M. H.; Hudson, J. A.; Leach, A.; Longridge, J. L.; Main, B. g.; Nicholson, S. J. 5 *Org. Chem. 1992 57 5158*).



General Method D - The compounds of formula I-D-5 in which M, X, Q^2 and Z are defined as above are conveniently prepared according to a reaction sequence as shown in Method D wherein the functional groups which may participate in the reactions are present in protected form where necessary, and the removal of such protective groups is completed at appropriate stages by methods well known to those skilled in the art. Thus, according to the procedure of Bernard, A. M.; Cocco, M. T.; Congiu, C.; Onnis, V.; Piras, P. P. *Synthesis 1998 317* aryloxy acetonitriles of structure XIII are reacted with acyl hydrazines of structure XIV in the presence of a base such as sodium ethoxide to provide products of formula XV. Compounds of formula XV undergo cyclization upon treatment with an acid such as *p*-toluenesulfonic acid to furnish phthalizones of formula XVI.


Treatment of the latter with a chlorinating agent such as phosphorous oxychloride yields iminoyl chlorides of the general formula XVII. Conversion to the invention compounds of formula I-D-5 is accomplished by treatment with a nucleophile of formula IX in the presence of a base such as sodium hydride or potassium hydroxide in a solvent such as toluene or tetrahydrofuran. The presence of a crown ether appropriate for the cation such as 18-crown-6 in the case of potassium often accelerates this reaction.

Method D



10 General Method E - The compounds of this invention having formula I-D-6 in which the R^1 , R^2 , M, G^3 , q, and X are defined as above are conveniently prepared via a reaction sequence as shown in Method E. Thus, readily prepared substituted 4-methylpyridazines XVIII are alkylated into substituted 2-aminocarbonyl pyridines of formula XIX by the use of a strong base such as lithium diisopropylamide, sodium hydride or DBU, followed by the addition of 4-halopyridines of formula (XIX). This method is most usefull in those cases wherein R^1 , R^2 and the pyridazine ring taken together form a phthalazine moiety, q is 1, the substituent is on position 2 of the pyridine ring, and said substituent is $-CON(R^6)_2$.


Method E



hal = F, Cl, Br or I


4-Methylpyridazines of formula XVIII are easily prepared from acids or esters of formula

5 XX via a three-step procedure involving (one) cyclization with hydrazine, (two) reaction with a dehydrating or chlorinating agent such as phosphorus pentoxide or phosphorous oxychloride and (three) addition of an nucleophile of formula IX:



4-Halopyridines of formula XIX are easily prepared by those skilled in the art.

10 Compound XIX-A in which Q is 1 and a substituent $-\text{CO}(\text{N}^6)^2$ is found on position 2 of the pyridine is obtained from the known 2-chlorocarbonyl-4-chloro-pyridine hydrochloride XXI and amine XXII as follows:



General Method F - Alternatively, the compounds of formula I-D-7-A through I-


15 D-7-E in which the R^1 , R^2 , M , Q^1 and X are defined as above are conveniently prepared via a reaction sequence as shown in Method F. This method is especially usefull in those cases in which B is a substituted or unsubstituted 4-pyridyl in which case XXIV is a 4-halopyridine. Thus, readily prepared compounds of the formula XXIII are alkylated to yield invention compounds of formula I-D-7-A by the use of a base such as sodium 20 hydride, DBU, or potassium carbonate, followed by the addition of halogenated

intermediates of formula XXIV. The resulting pyridazines of formula I-D-7-A are then optionally hydrolyzed and decarboxylated by treatment with hot aqueous acid or base to yield invention compounds of formula I-D-7-B.

Alternatively the treatment of I-D-7-A with aqueous base such as NaOH at ambient 5 temperature followed by acidification yields invention compounds of structure I-D-7-C. This acid may then be treated with a diazoalkane to yield invention compounds I-D-7-D or with ammonia or a primary or secondary amine in the presence of a coupling agent such as DCC (dicyclohexylcarbodiimide) to yield invention compounds of structure I-D-7-E.


Method F

10




Intermediates of formula XXIII are prepared as follows by methods well known to those skilled in the art. Thus readily available diesters of formula XXVI are treated with hydrazine in a suitable solvent to yield a compound of the formula XXVII. Reaction of XXVII with a suitable chlorinating agent such as POCl₃ yields a 1,4-dichloropyridazine which is then reacted with a nucleophile IX as a melt or in the presence of a suitable base such as triethylamine or N-methylmorpholine to yield XXVIII. See *J. Chem Soc.* 1948, 777-782 for a preparation of XXVIII in which M is 4-chlorophenyl, X is NH and R¹ and R² taken together with the pyrazine ring is phthalazine. Alternatively a brominating agent 15 such as POBr₃ is used and the intermediates contain bromine rather than chlorine. It is expected that suitable iodinating agents are equally usefull in this process. The key intermediate of structure XXIII is formed from XXVIII upon addition of Meldrum's acid 20

in the presence of base such as NaH, followed by ethanolysis in the presence of a base such as triethylamine.




General Method G - Alternatively, the compounds of formula I-D-8 in which the 5 R^1 , R^2 , M , X , R^6 and G^3 are defined as above are conveniently prepared via a reaction sequence as shown in Method G. Thus the methods described in Martin, I; Anvelt, J.; Vares, L.; Kuehn, I.; Claesson, A. *Acta Chem. Scand.* 1995, 49, 230-232 or those of methods A or B above by substituting readily available pyridine-4-carboxylic ester XXIX for I-D are used to convert XXIX into XXX. Reduction of the ester as described by 10 Martin, et al. above is next done with a mild reducing agent such as $NaBH_4$ such that the amide substituent is left unchanged to yield alcohol XXXI. Alcohol XXXI is then heated in a base such as DBU with chloropyridazine XXVIII to yield the invention compound with formula I-D-8.

Method G


General Method H – Invention compounds having formula I-D-9 in which the R¹,

R², M, X, R⁶, q, and G³ are defined as above and W is a bond or -CH₂- are conveniently
 5 prepared via a reaction sequence as shown in Method H. This method is especially useful
 when q is 1 and XXXII is 4-chloropyridine. Alternatively, other 4-halopyridines such as
 10 4-fluoropyridine can be used in this process. Thus readily available 4-chloropyridines
 XXXII are converted to intermediates of formula XXXIII by using the general procedures
 of methods A or B above by substituting the 4-chloropyridine for I-D. Reaction of
 15 XXXIII with either potassium or sodium hydrogen sulfide yields a thiol having formula
 XXXIV. Alternatively, the alcohol function of intermediate XXXI from method G is
 converted to a leaving group by reaction with methanesulfonyl chloride and a suitable
 base such as triethylamine and the resultant intermediate is reacted with either potassium
 or sodium hydrogen sulfide to yield a thiol having formula XXXV. Either thiol have
 formula XXXIV or formula XXXV is reacted with intermediate XXVIII from method F
 and a suitable base such as diisopropylethylamine in DMF or other suitable solvent to
 yield I-D-9.

Method H




General Method I - Invention compounds having formula I-D-10 in which the R^1 , R^2 , M , X , R^6 , q , and G^3 are defined as above are conveniently prepared via a reaction sequence as shown in Method I. Thus alcohol of formula XI from method C is reacted with methanesulfonyl chloride in the presence of a suitable base followed by potassium or sodium hydrogen sulfide to yield thiol XXXVI. The thiol is then reacted with 4-chloropyridine XXXIII from method H in the presence of a suitable base such as triethylamine to yield invention compound I-D-10. Analogous optionally substituted 4-fluoropyridines may be used instead of XXXIII. Alternatively, XI is converted to halo intermediate of formula XXXVII by methods well known to those skilled in the art and XXXVII is reacted with thiol XXXVI from method H to yield I-D-10. Intermediate XXXVII can also be converted to intermediate XXXVI by treatment with KHS or NaHS.



General Method J - Invention compounds having formula I-D-11 or I-D-12 in which the R¹, R², M, X, W, and G³ are defined as above and a sulfoxide or sulfone within the structure are conveniently prepared via a reaction sequence as shown in Method J.

5 Reaction of compounds of this invention that contain a thio group either as part of a substituent G¹, G³, or G⁴ or as part of Y as shown in the representative structure XXXVIII can be converted to the invention compounds with a sulfoxide moiety such as I-D-11 by treatment with one equivalent of m-chloroperbenzoic acid in methylene chloride or chloroform (MCPBA, Synth. Commun., 26, 10, 1913-1920, 1996) or by treatment with 10 sodium periodate in methanol/water at between 0 °C and room temperature (J. Org. Chem., 58, 25, 6996-7000, 1993). The expected side products consisting of mixtures of various N oxides and the sulfone I-D-12 can be removed by chromatography. The sulfone I-D-12 is obtained by the use of an additional equivalent of MCPBA or preferably by use of potassium permanganate in acetic acid/water (Eur. J. Med. Chem. Ther., 21, 1, 5-8, 15 1986) or by use of hydrogen peroxide in acetic acid (Chem. Heterocycl. Compd., 15, 1085-1088, 1979). In those cases that unwanted N oxides become a significant product, they can be converted back to the desired sulfoxides or sulfones by hydrogenation in ethanol/acetic acid with palladium on carbon catalysts (Yakugaku Zasshi, 69, 545-548, 1949, Chem. Abstr. 1950, 4474).


Method J



EXPERIMENTAL:

5

Example 1: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide




10 To a 3-necked flask charged with 1-(4-chloroanilino)-4-[(2-methyl-4-pyridyl)methyl] phthalazine (for preparation see Novartis patent WO98/35958, 11.02.98) (0.828 g, 2.39 mmol) in anhydrous N-methylformamide (4.8 mL) was added concentrated sulfuric acid (0.12 mL, 2.39 mmol) and iron (II) sulfate heptahydrate (0.33 g, 1.19 mmol). Hydrogen peroxide (0.256 mL, 8.35 mmol; 30 wt. % solution in water) was added dropwise to keep the internal temperature below 80°C. The resultant wine color reaction was then stirred at 70°C for 5h. The reaction mixture was cooled to RT and quenched with 15 10% aqueous sodium hydroxide (10 mL) followed by 10% aqueous ammonia (~100 mL). The resultant brown precipitate was filtered through a pad of celite, and the filtrate was extracted with 10% methanol-dichloromethane (3 x 100 mL). The combined organic phases were washed with water (2 x 50 mL) and brine (1 x 50 mL), dried over MgSO₄, 20 filtered, and evaporated *in vacuo*. The crude oil was purified by flash column chromatography (10% acetone-dichloromethane followed by 1:4:20 v/v methanol-acetone-dichloromethane). Recrystallization from methanol afforded 0.165 g (0.404 mmol, 17% yield) of the title compound as a yellow solid. ¹H-NMR (DMSO-d₆) 9.28 (s, 1H), 8.70 (d,

$J = 4.9, 1\text{H}$), 8.58 (d, $J = 7.4, 1\text{H}$), 8.49 (d, $J = 5.4, 1\text{H}$), 8.12 (d, $J = 8.4, 1\text{H}$), 7.89 to 7.99 (m, 5H), 7.51 (dd, $J = 5.1, 1.7, 1\text{H}$), 7.38 (dd, $J = 7.1, 1.9, 2\text{H}$), 4.67 (s, 2H), 2.75 (d, $J = 4.9, 3\text{H}$); MS ES 404 ($\text{M}+\text{H}$)⁺, calc. 403; TLC (1:4:15 v/v methanol-acetone-dichloromethane) $R_f = 0.74$.

5


Example 2: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide



The procedure used for the preparation of Example 1, but replacing N-methylformamide with formamide, was used to prepare the title compound (0.065 g, 0.167 mmol, 19% yield). ¹H-NMR (DMSO-d₆) 9.27 (s, 1H), 8.58 (d, $J = 7.6, 1\text{H}$), 8.49 (d, $J = 4.5, 1\text{H}$), 8.12 (d, $J = 7.7, 1\text{H}$), 8.06 (broad s, 1H), 7.90 to 8.00 (m, 5H), 7.59 (broad s, 1H), 7.53 (dd, $J = 5.0, 1.5, 1\text{H}$), 7.37 (d, $J = 8.7, 2\text{H}$), 4.66 (s, 2H); MS ES 390 ($\text{M}+\text{H}$)⁺, calc. 389; TLC (1:4:15 v/v methanol-acetone-dichloromethane) $R_f = 0.31$.

15


Example 3: Preparation of 1-(4-chlorophenylamino)-4-(3-pyridylmethoxy)phthalazine



A dry 50-mL round-bottomed flask was equipped with a stir bar and an argon inlet. The flask was charged with 1-chloro-4-(4-chlorophenylamino)-phthalazine (R. D. Haworth and S. Robinson, J. Chem. Soc. 1948, pp.777-782) (2.00 g; ~6.12 mmol), 3-pyridylcarbinol (Aldrich) (10.02 g, 91.85 mmol), and DBU (18.3 mL, ~18.7 g. ~123 mmol). The reaction was heated at 125 C for 28 h. The mixture was cooled to room temperature and distilled water (400 mL) was added with stirring. The aqueous phase was extracted with


ethyl acetate (3 X 300 mL). The combined organics were dried ($MgSO_4$) and concentrated to yield a tan solid, which was purified by silica gel chromatography (100% dichloromethane \rightarrow 50% acetone/dichloromethane) to give the clean desired compound as a white solid (1.24 g, 3.42 mmol; 56% yield). TLC (20% acetone/dichloromethane): R_f 5 0.48.

Example 4: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxyethyl]pyridin-2-yl carboxylic acid methylamide



10

Step 1: Preparation of 1-(4-chlorophenylamino)-4-(4-pyridylmethoxy)-phthalazine




The general procedure used for the preparation of Example 3 was used in step 1 of 15 the preparation of Example 4 from 1-chloro-4-(4-chlorophenylamino)phthalazine and 4-pyridyl-carbinol; (87% yield). TLC (20% acetone/dichloromethane): R_f 0.26.

Step 2:

Caution - this reaction is potentially explosive and latent violent exotherms have been noted, especially if the reaction is heated and unreacted hydrogen peroxide is present. The product of step 1 above (0.600 g, 1.65 mmol) was dissolved in 16.5 ml of N-methyl-formamide. The reaction was charged with concentrated sulfuric acid (0.264 ml, 4.96 mmol) followed by $FeSO_4 \cdot 7H_2O$ (0.115 g, 0.413 mmol). The solution was stirred at ambient temperature for 15 min then 30% wt. hydrogen peroxide/water (0.338 ml, 3.31


mmol) was added (exotherm noted). TLC analysis after 1 h indicates the reaction is 50% done. The reaction was again charged with concentrated sulfuric acid (0.264 ml, 4.96 mmol) followed by FeSO₄·7H₂O (0.115 g, 0.413 mmol). To the reaction is added 6 aliquots of 30% wt. hydrogen peroxide/water (each aliquot is 0.338 ml, 3.31 mmol) over 3 h. The opaque brown reaction was stirred for 24 h at 30 C. TLC analysis now indicates no starting material is present. The reaction was quenched with saturated potassium carbonate (100 ml) and the solids filtered off washing with water. The aqueous layer was extracted with diethyl ether (3 X 175 ml), and the combined organics dried (MgSO₄) and concentrated to give an orange solid. The crude product was purified by silica gel chromatography (100% dichloromethane → 10% acetone/dichloromethane) to give the clean desired compound as a tan solid (64 mg, 0.152 mmol; 9% yield). TLC (10% acetone/dichloromethane): R_f = 0.38.

Example 5: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-yl]oxymethyl]pyridin-2-yl carboxylic acid amide




The general procedure used for the preparation of Example 4 was used to prepare 5 from 1-(4-chlorophenylamino)-4-(4-pyridylmethoxy)phthalazine and formamide; (10% yield). TLC (dichloromethane/acetone/triethylamine 7.5 : 1.0 : 0.5): R_f = 0.42.

Example 6: Preparation of 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid methylamide




The procedure used for the preparation of Example 1 was used to prepare the title compound (0.15 g, 0.33 mmol, 33% yield) from 1-(3-bromoanilino)-4-[(2-methyl-4-pyridyl)methyl] phthalazine (for preparation see Novartis patent WO98/35958, 11.02.98).
¹H-NMR (DMSO-d₆): 9.30 (s, 1H), 8.70 (d, J = 5.1, 1H), 8.58 (d, J = 7.7, 1H), 8.49 (d, J = 5.3, 1H), 8.35 (t, 1.8, 1H), 8.13 (d, J = 8.3, 1H), 7.88 to 8.01 (m, 4H), 7.51 (dd, J = 5.0, 1.5, 1H), 7.29 (t, J = 8.2, 1H), 7.18 (d, J = 7.7, 1H), 4.68 (s, 2H), 2.75 (d, J = 4.9, 3H); MS ES 10 449 (M+H)⁺, calc. 448; TLC (20% acetone-dichloromethane) R_f = 0.37.

Example 7: Preparation of 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid amide




15 The procedure used for the preparation of Example 1, but replacing N-methylformamide with formamide, was used to prepare the title compound (0.059 g, 0.13 mmol, 10.6% yield) from 1-(3-bromoanilino)-4-[(2-methyl-4-pyridyl)methyl]phthalazine (for preparation see Novartis patent WO98/35958, 11.02.98). ¹H-NMR (DMSO-d₆) 9.31 (s, 1H), 8.58 (d, J = 7.7, 1H), 8.49 (d, J = 5.3, 1H), 8.35 (s, 1H), 8.13 (d, J = 7.5, 1H), 8.05 (broad s, 1H), 7.89 to 7.99 (m, 4H), 7.59 (broad s, 1H), 7.53 (dd, J = 5.1, 1.5, 1H), 7.29 (t, J = 8.0, 1H), 7.18 (d, J = 7.8, 1H), 4.68 (s, 2H); MS ES 434/436 (M+H)⁺ w/ 1Br, calc. 433; TLC (1:4:15 v/v methanol-acetone-dichloromethane) R_f = 0.59.

Example 8: Preparation of 1-(4-chlorophenylamino)-4-[(2-phenyl-4-pyridyl)methyl]phthalazine.




5

Step 1: Preparation of 2-(2-phenylpyridin-4-ylidene)indan-1,3-dione



Under exclusion of air, a mixture of phthalic anhydride (4.38 g, 29.5 mmol) and 2-phenyl-4-picoline (5.0 g, 29.5 mmol) was heated to 200°C. The reaction melt was stirred at 200°C for 14h until a yellow precipitate was formed. The reaction was cooled to 100°C and ethanol (300 mL) was added. The resultant brown mass was refluxed in ethanol for 1h and sonicated in a water bath to break up the compound. The precipitate was filtered and triturated in ethanol (100 mL) to give the title compound as a yellow solid (3.2 g, 10.7 mmol, 36% yield). ¹H-NMR (DMSO-d₆) 12.06 (broad s, 1H), 9.04 (d, J = 1.3, 1H), 8.68 (dd, J = 6.7, 1.3, 1H), 8.17 (d, J = 6.7, 1H), 7.79 (dd, J = 8.0, 5.2, 2H), 7.61 to 7.64 (m, 3H), 7.45 to 7.53 (m, 4H); MS ES 300 (M+H)⁺, calc. 299; TLC (1:2:8 v/v methanol-acetone-dichloromethane) *R*_f = 0.32.

Step 2: Preparation of 4-[(2-phenyl-pyridinyl)methyl]-1(2H)-phthalazinone



20

A mixture of 2-(2-phenylpyridin-4-ylidene)-indan-1,3-dione (3.1 g, 10.4 mmol) and hydrazine hydrate (9.7 mL) was stirred at 130°C under argon for 5 h. The reaction mixture was cooled and filtered. The resultant tacky solid was dissolved in ethyl acetate (250 mL) and then washed with water (2 x 50 mL) and brine (1 x 50 mL). The organic


layer was dried over MgSO₄, filtered, and evaporated *in vacuo*. Trituration from ether afforded the title compound as a beige solid (2.82 g, 9.0 mmol, 86% yield). ¹H-NMR (DMSO-d₆) 12.59 (broad s, 1H), 8.52 (d, J = 4.6, 1H), 8.24 (dd, J = 7.7, 1.0, 1 H), 7.95 to 8.03 (m, 4H), 7.78 to 7.91 (m, 2H), 7.40 to 7.49 (m, 3H), 7.21 (d, J = 6.5, 1H), 4.39 (s, 2H); MS ES 314 (M+H)⁺, calc.313; TLC (1:2:8 v/v methanol-acetone-dichloromethane) *R_f* = 0.40.

Step 3:

A mixture of 4-chloroaniline (1.63 g, 12.76 mmol), phosphorus pentoxide (1.81 g, 10 12.76 mmol) and triethylamine hydrochloride (1.76 g, 12.76 mmol) was heated and stirred under argon at 200°C for 1.5 h or until a homogenous melt has formed. To the melt was added 4-[(2-phenyl-pyridinyl)-methyl]-1(2H)-phthalazinone (1.0 g, 3.19 mmol) and the reaction mixture was stirred at 200°C for 2h. The resultant solid black mass was cooled to 100°C. Methanol (~100 mL) and water (~400 mL) were added and the reaction mixture 15 was sonicated until the black mass has become soluble. Dichloromethane (250 mL) was then added to form a biphasic layer, and concentrated ammonia (~5mL) was added to adjust the reaction to pH = 8. The organic layer was separated, and the aqueous layer was extracted with dichloromethane (3 x 100 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. Purification by flash column chromatography 20 (15% acetone/ dichloromethane) yielded 1.25 g (2.96 mmol, 93% yield) of the title compound as a beige solid. ¹H-NMR (DMSO-d₆) 9.26 (s, 1H), 8.57 (d, J = 8.1, 1H), 8.49 (d, J = 4.9, 1H), 8.19 (d, J = 8.2, 1H), 7.89 to 8.02 (m, 7H), 7.36 to 7.48 (m, 5H), 7.20 (dd, J = 5.0, 1.3, 1H), 4.60 (s, 2H); MS ES 423 (M+H)⁺, calc.422; TLC (20% acetone-dichloromethane) *R_f* = 0.29.

25

Example 9: Preparation of 1-[4-(4-pyridyloxy)phenylamino]-4-(4-pyridylmethyl)phthalazine




A mixture of 1-chloro-4-(4-pyridylmethyl)phthalazine (for preparation see Novartis 30 patent WO98/35958, 11.02.98) (0.540 g, 2.11 mmol) and 4-(4-aminophenoxy)pyridine

(1.18 g, 6.33 mmol) in anhydrous 1-butanol (8.4 mL) was stirred under argon at 130°C for 18h. The reaction mixture was quenched with saturated aqueous potassium carbonate (~50 mL) and then extracted with dichloromethane (3 x 100 mL). The combined organic phases were dried over MgSO₄, filtered, and concentrated. Purification by flash column chromatography in 7: 11: 2 v/v acetone-dichloromethane-methanol provided the title compound as an oil (0.340 g, 0.84 mmol, 40% yield). ¹H-NMR (DMSO-d₆) 9.26 (s, 1H), 8.58 (d, J = 8.3, 1H), 8.41 to 8.44 (m, 4H), 8.10 (d, J = 8.2, 1H), 7.90 to 8.03 (m, 4H), 7.30 (d, J = 5.9, 2H), 7.17 (d, J = 9.2, 2H), 6.91 (d, J = 5.8, 2H), 4.56 (s, 2H); MS ES 406 (M+H)⁺, calc. 405; TLC (1:7:12 v/v methanol-acetone-dichloromethane) *R*_f = 0.08.


10

Example 10: Preparation of 1-(indan-5-ylamino)-4-(4-pyridylmethyl)phthalazine




The procedure used for the preparation of Example 9 was used to prepare the title compound (0.06g, 0.17 mmol, 4.3% yield) by substituting 5-aminoindane for 4-(4-aminophenoxy)pyridine. ¹H-NMR (DMSO-d₆) 9.01 (s, 1H), 8.56 (d, J = 7.2, 1H), 8.42 (dd, J = 4.3, 1.4, 2H), 8.05 (d, J = 8.6, 1H), 7.85 to 7.95 (m, 3H), 7.56 (dd, J = 8.3, 2.0, 1H), 7.28 (dd, J = 4.3, 1.4, 2H), 7.16 (d, J = 8.1, 1H), 4.54 (s, 2H), 2.79 to 2.89 (m, 4H), 1.96 to 2.07 (m, 2H); MS ES 353 (M+H)⁺, calc. 352; TLC (3:17:80 v/v methanol-acetone-dichloromethane) *R*_f = 0.20.

Example 11: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dihydrochloride



A 50 mL, round-bottomed flask was equipped with a stir bar. To the flask was 5 added BAY 50-9193 (250 mg, 0.62 mmol) in hot MeOH (10 mL). HCl in MeOH (3.8 N) was added dropwise until solution was pH 2. The solution was concentrated to half-volume by rotary evaporation. Ether was added until the solution became cloudy. The solution was cooled to RT before filtering. The orange solid was washed with 2:1 ether:MeOH (5 mL) followed by ether (5 mL). The solid was dried under HV overnight at 10 50 °C. Desired compound (61mg, 0.13 mmol, 21% yield): m.p. 255 °C (dec.); ¹H NMR (DMSO-*d*₆) 8.93-8.96 (m, 1H), 8.73-8.74 (m, 1H), 8.53 (d, *J* = 5.3, 1H), 8.37-8.40 (m, 1H), 8.20-8.23 (m, 2H), 8.04 (s, 1H), 7.55-7.67 (m, 5H), 4.77 (s, 2H), 2.76 (d, *J* = 4.6, 3H); ES MS (M+H)⁺ = 404; TLC (dichloromethane-acetone, 90:10): R_f = 0.44; *Anal.* calc'd. C₂₂H₂₂N₅OCl₃·0.5H₂O. C 54.39, H 4.36, N 14.42, Cl 21.89; found C 54.39, H 4.37, N 15 14.30, Cl 20.17.

Example 12: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dimethanesulfonate



20 A 50 mL, round-bottomed flask was equipped with a stir bar. To the flask was added BAY 50-9193 (250 mg, 0.62 mmol) in hot MeOH (10 mL). Methanesulfonic acid (90 μ L, 1.24 mmol) was added to solution. The solution was concentrated to half-volume

by rotary evaporation. Ether was added until the solution became cloudy. The solution was cooled to 0 °C before filtering. The yellow solid was washed with ether (5 mL). The solid was dried under HV overnight at 50 °C. Desired compound (309 mg, 0.52 mmol, 84% yield): m.p. 245-249 °C; ¹H NMR (DMSO-*d*₆) 8.82 (dd, *J* = 1.8, 5.2, 1H), 8.72-8.76 (m, 1H), 8.54 (d, *J* = 5.1, 1H), 8.39-8.42 (m, 1H), 8.20-8.27 (m, 1H), 8.04 (s, 1H), 7.55-7.65 (m, 5H), 4.75 (s, 2H), 2.76 (d, *J* = 4.7, 3H), 2.33 (s, 6H); ES MS: (M+H)⁺ = 404; TLC (dichloromethane-acetone, 90:10): R_f = 0.45; Anal. calc'd. C₂₄H₂₆N₅O₇S₂Cl·0.6H₂O C 47.57, H 4.51, N 11.56, Cl 5.85, S 10.58%; found C 47.57, H 4.50, N 11.43, Cl 5.88, S 10.88.


10

Example 13: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dihydrochloride

A 50mL, round-bottomed flask was equipped with a stir bar. To the flask was added BAY 50-9323 (250 mg, 0.16 mmol) in hot MeOH (10 mL). HCl in MeOH (3.8N, ~2 mL) was added dropwise until solution was pH 2. The solution was concentrated to half-volume by rotary evaporation. Ether was added until solution became cloudy. The solution was cooled to RT before filtering. The orange solid was washed with 2:1 ether:MeOH (~5 mL) then ether (~5 mL). Solid was dried in vacuum oven overnight at 50 °C. Desired compound (34 mg, 0.073 mmol; 11% yield); mp = 180-198 °C; ¹H NMR (DMSO-*d*₆) 9.00-9.03 (m, 1H), 8.54 (d, *J* = 5.2, 1H), 8.37-8.41 (m, 1H), 8.20-8.23 (m, 1H), 8.09 (s, 1H), 8.05 (s, 1H), 7.62 (dd, *J* = 7.7, 25, 6H), 4.78 (s, 2H); ES MS (M+H)⁺ = 390; TLC (dichloromethane-acetone, 95:5); R_f = 0.44; Anal. Calc for C₂₁H₁₈N₅OCl₃. C 54.51, H 3.92, N 15.13, Cl 22.98, found C 54.31, H 4.03, N 13.93, Cl 22.72.


25

Example 14: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dimethanesulfonate




A 25 mL, round-bottomed flask was equipped with a stir bar. To the flask was added BAY 50-9323 (250 mg, 0.64 mmol) in hot MeOH (8 mL). Methanesulfonic acid (93 μ L, 1.28 mmol) was added to solution. Ether was added until the solution became cloudy. Solution was cooled to 0 $^{\circ}$ C before filtering. The yellow solid was washed with 5 ether (5 mL). The solid was dried under HV overnight at 50 $^{\circ}$ C. Desired compound (382 mg, 0.66 mmol, 99% yield): m.p. 156-161 $^{\circ}$ C; 1 H NMR (DMSO- d_6) 8.82 (dd, J = 2.0, 5.5, 1H), 8.55 (d, J = 4.5, 1H), 8.39-8.42 (m, 1H), 8.22-8.25 (m, 2H), 8.09 (s, 1H), 8.04 (s, 1H), 7.57-7.65 (m, 5H), 4.75 (s, 2H), 2.32 (s, 6H); ES MS: (M+H) $^{+}$ = 390; TLC (dichloromethane-acetone, 90:10): R_f = 0.18; Anal. calc'd C₂₃H₂₄N₅O₇S₂Cl \cdot 1.5H₂O C 10 45.38, H 4.46, N 11.50, Cl 5.82, S 10.53; found C 45.38, H 4.28, N 11.27, Cl 5.85, S 10.93.

Example 15: Preparation of 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide dihydrochloride




15 A 50mL, round-bottomed flask was equipped with a stir bar. To the flask was added BAY 50-9644 (300 mg, 0.74 mmol) in hot EtOH (10 mL). HCl in MeOH (3.8N, ~2 mL) was added dropwise until solution was pH 2. The solution was concentrated to half-volume by rotary evaporation. Ether was added until solution became cloudy. The solution was cooled to RT before filtering. The yellow solid was washed with ether (~5 mL). The 20 solid was dried in vacuum oven overnight at 50 $^{\circ}$ C. Desired compound (320 mg, 0.67 mmol; 91% yield); mp = 143-145.2 $^{\circ}$ C; 1 H NMR (DMSO- d_6) 11.87 (s, 1H), 9.18 (d, J = 8.8, 1H), 8.66 (d, J = 5.2, 1H), 8.40 (d, J = 8.8, 1H), 8.18-8.30 (m, 4H); 7.77 (dd, J = 1.3, 5, 1H), 7.74 (s, 1H); 7.55-7.75 (m, 4H), 5.65 (s, 2H); ES MS (M+H) $^{+}$ = 406; TLC (dichloromethane-acetone, 95:5); R_f = 0.184; Anal. Calc for C₂₁H₁₈N₅O₂Cl \cdot 0.8H₂O C 25 51.07, H 4.02, N 14.18, Cl 21.53, found C 51.07, H 4.13, N 14.77, Cl 20.42.

Example 16: Preparation of 4-[4-(4-Chlor phenylamino)phthalazin-1-yl oxyxymethyl]pyridin-2-yl carb xylic acid amide dimethanesulfonate



A 50mL, round-bottomed flask was equipped with a stir bar. To the flask was 5 added BAY 50-9644 (300 mg, 0.74 mmol) in hot EtOH (10 mL). Methanesulfonic acid (0.1 mL, 1.48 mmol) was added to solution. The solution was concentrated to half-volume by rotary evaporation. Ether was added until solution became cloudy. The solution was cooled to RT before filtering. The yellow solid was washed with ether (~5 mL). The solid was dried in vacuum oven overnight at 50 °C. Desired compound (393 mg, 0.66 mmol; 10 89% yield); mp = 75-80 °C; ¹H NMR (DMSO-d₆) 11.23 (s, 1H), 8.81 (d, J = 9.2, 1H), 8.67 (d, J = 4.8, 1H), 8.43 (d, J = 9.2, 1H), 8.24-8.32 (m, 2H), 8.18 (s, 1H), 8.17 (s, 1H), 7.78 (dd, J = 1.5, 5.1, 1H), 7.74 (s, 1H), 7.59 (dd, J = 9.0, 18.9Hz, 4H), 5.66 (s, 2H), 2.37 (s, 6H); ES MS (M+H)⁺ = 406; TLC (dichloromethane-acetone, 95:5); R_f = 0.195; Anal. Calc for C₂₃H₂₄N₅O₈S₂Cl•1.6H₂O C 44.06, H 4.37, N 11.17, Cl 5.65, S 24.51, found C 44.06, H 15 4.35, N 11.18, Cl 5.74, S 10.64.


Example 17: Preparation of 1-(4-chlorophenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine



20 A mixture of 1-chloro-4-(4-chlorophenylamino)phthalazine hydrochloride (R. D. Haworth and S. Robinson, J. Chem. Soc. 1948, pp.777-782) (275 mg; 0.84 mmol), 5-(4-


pyridyl)—1H-1,2,4-triazole-3-thiol (303 mg, 1.67 mmol), diisopropylethylamine (3 ml) and dimethylformamide (3 ml) was heated at 100 °C under argon for 15 hr. The resultant product residue was dissolved in ethyl acetate and the resultant solution was washed with water and brine, dried over magnesium sulfate and then evaporated *in vacuo*. The residue of crude product was purified by chromatography on silica gel using 4% methanol in methylene chloride to yield 29 mg of pure title compound, R_f 0.36 (10% methanol in methylene chloride).

Example 18: Preparation of 1-(4-isopropylphenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine



Using the method of example 17 and 1-chloro-4-(4-isopropylphenylamino)phthalazine (250 mg, 0.84 mmol) rather than 1-chloro-4-(4-chlorophenylamino)phthalazine hydrochloride yielded 21 mg of the pure title compound, R_f 0.28 (10% methanol in methylene chloride).

Example 19: Preparation of 1-(4-chlorophenylamino)-4-(4-pyridylsulfonyl)phthalazine




1-Chloro-4-(4-chlorophenylamino)-phthalazine (R. D. Haworth and S. Robinson, J. Chem. Soc. 1948, pp.777-782) (2.00 g; ~6.12 mmol) can be melted together with one equivalent of 4-mercaptopypyridine at about 140 °C for about 10-30 min. to yield a residue which is dissolved in ethyl acetate, washed with aqueous sodium carbonate and then

evaporated *in vacuo*. The residue can be purified by chromatography on silica gel using a gradient of pure methylene chloride to 50% acetone in methylene chloride to yield pure 1-(4-chlorophenylamino)-4-(4-pyridylthio)phthalazine. The intermediate thioether can be stirred as a solution in acetic acid as 30% aqueous hydrogen peroxide is added in small portions until TLC analysis indicates that all starting material has been consumed. The crude product is isolated by dilution with ethyl acetate, washing with aqueous carbonate solution to remove acetic acid and evaporation *in vacuo*. Pure invention compound can be obtained by chromatography on the residue on silica gel using methylene chloride/acetone gradients.

10


Example 20: Preparation of 1-(4-chlorophenylamino)-4-(4-pyridylsulfinyl)phthalazine



Following the general procedure of Proudfoot, et al. (*J. Org. Chem.* 58, 6996-700, 15 1993), 1-(4-chlorophenylamino)-4-(4-pyridylthio)phthalazine from example 19 can be stirred with one equivalent of sodium periodate in methanol/water for several days at room temperature to yield the title compound which can be isolated in pure form by chromatography on silica gel using methylene chloride/methanol gradients.

20

Example 21: Preparation of 1-(4-chlorophenylamino)-4-(4-pyridylmethoxy)pyridazine




Step 1: To a mixture of 3,6- dibromo-pyridazine (500 mg, 2.10mmol, for preparation see Pwdrali et al.; *J.Org. Chem.*; 23, 1958; 778) and 4-pyridylcarbinol (229 mg, 25 2.10 mmol) in anhydrous tetrahydronfuran (10 mL) at 0 °C under argon was added sodium

hydride (302 mg, 12.6 mmol). The reaction mixture was warmed up to RT and then was stirred at 50 °C under argon for 6h. After cooled to 0 °C, the resultant orange mixture was diluted with ethyl acetate (20 mL) and then excess sodium hydride was quenched by water until no bubble occurred. The organic layer was collected and washed by brine (3 x 10 mL) and dried over anhydrous Na₂SO₄, filtered, and evaporated *in vacuo*, which afforded 400 mg (1.50 mmol, 71% yield) of 1-bromo-4-(4-pyridylmethoxy)pyridazine as an oil. The crude product was pure enough to carried out next step reaction without further purification. ¹H-NMR (MeOH-d₄) 8.52-8.54 (m, 2H), 7.80 (d, 1H), 7.52-7.54 (m, 2H), 7.25 (d, 1H), 5.60 (s, 2H); MS LC 266 M+, 269 (M+3H)⁺, cacl. 266; TLC (3:2 v/v ethyl acetate-hexanes) R_f = 0.20.

Step 2: To 1-bromo-4-(4-pyridylmethoxy)pyridazine (50 mg, 0.19 mmol) in toluene (3 mL) was added 4-chloroaniline (29mg, 0.22mmol), catalytical amount of (R) - (+)-2,2'-bis(diphenyl phosphino)-1,1'-binaphthyl (1mg), tris(dibenzylideneacetone)-dipalladium(0) (0.6 mg) and sodium t-butyloxide (26 mg, 0.27mmol). The reaction mixture was heated at 80 °C for 12h under argon. The reaction mixture became deep brown upon heating. The mixture was cooled to RT, diluted with ethyl acetate (10 mL), washed by brine and the organic layer was dried over Na₂SO₄, and the solvent was evaporated *in vacuo*. The crude mixture was purified by preparative thin layer plate to afford the title compound (6 mg, yield 10%). ¹H-NMR (MeOH-d₄), 8.51 (d, 2H), 7.61(d, 2H) 7.52(dd,2H), 7.15-7.25(m,4H), 5.49(s,2H); MS ES 313 (M+H)⁺, 315 (M+3H)⁺, 316 (M+4H)⁺, calc. 312; TLC (5:95 v/v methanol-methylene chloride) R_f = 0.2.

Example 22: Preparation of 1-(indan-5-ylamino)-4-(4-pyridylcyanomethyl)phthalazine




25

Step 1: 4-Pyridylacetonitrile hydrochloride (5.00 g, 32.3 mmol) in 40 mL of THF was sonicated for 10 min, and the mixture was added to 10 mL THF solution of NaH (1.55 g, 64.7 mmol) using dripping funnel while the temperature was kept below 15 °C. After the

addition, the mixture was cooled to 0 °C and 1,4-dichlorophthalazine (3.22 g, 24.3 mmol) was added to the mixture. The mixture turned into red instantly. The reaction was continued for another 4 hrs, and the mixture was poured in cold NH₄Cl solution. The resulting red solid was filtered, washed with H₂O, and dried to give 4.4 g of 1-chloro-4-(4-pyridylcyanomethyl)phthalazine (65%); mp 265 °C (dec); ¹H NMR (CDCl₃) δ 6.00 (s, 1 H), 7.39-8.60 (m, 8 H); LC/MS MH⁺ 281.4.

Step 2: A mixture of 1-chloro-4-(4-pyridylcyanomethyl)phthalazine (570 mg, 2.03 mmol) and 5-aminoindan (320 mg, 2.40 mmol) in 20 mL of n-butanol were refluxed for 10 hrs. The solvent was evaporated under reduced pressure and the solid was dissolved in 50 mL of dichloromethane and washed with 4 M KOH solution and H₂O. The organic layer was separated and dried (MgSO₄). The product (420 mg, 55%) was purified by prep TLC on silicon gel using EtOAc/MeOH (20:1) as the eluent. R_f 0.7; mp 122-123 °C; ¹H NMR (CD₃OD) δ 2.15 (m, 2 H), 2.85 (m, 4 H), 7.20-8.60 (m, 12 H); LC/MS MH⁺ 378.4.

15 **Example 23: Preparation of 1-(benzothiazol-6-ylamino)-4-(4-pyridylcyanomethyl)phthalazine**



The procedure used for the preparation of Example 22 was used to prepare the title compound by substituting 6-aminobenzothiazole (360 mg, 2.40 mmol) for 5-aminoindan and 1-chloro-4-(4-pyridylmethyl)phthalazine (for preparation see Novartis patent WO98/35958, 11.02.98, 520 mg, 2.03 mmol) for 1-chloro-4-(4-pyridylcyanomethyl)phthalazine. Pure product had the characteristics: mp 163-164 °C; R_f 0.6 (EtOAc:MeOH = 20:1); ¹H NMR (CD₃OD) δ 4.65 (s, 2 H), 7.38 (s, 2 H), 7.96 (m, 5 H), 8.40 (s, 2 H), 8.49 (m, 2 H), 8.82 (s, 2 H), 9.11 (s, 2 H); LC/MS MH⁺ 370.4.

Biological Protocols and *in vitro* Test Data**KDR Assay:**

The cytosolic kinase domain of KDR kinase was expressed as a 6His fusion protein in Sf9 insect cells. The KDR kinase domain fusion protein was purified over a Ni++ chelating column. Ninety-six well ELISA plates were coated with 5 µg poly(Glu4;Tyr1) (Sigma Chemical Co., St Louis, MO) in 100 µl HEPES buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.02% Thimerosal) at 4° overnight. Before use, the plate was washed with HEPES, NaCl buffer and the plates were blocked with 1% BSA, 0.1% 10 Tween 20 in HEPES, NaCl buffer.

Test compounds were serially diluted in 100% DMSO from 4 mM to 0.12 µM in half-log dilutions. These dilutions were further diluted twenty fold in H2O to obtain compound solutions in 5% DMSO. Following loading of the assay plate with 85 µl of assay buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 10 mM MgCl₂, 3 mM MnCl₂, 0.05% 15 glycerol, 0.005% Triton X-100, 1 mM -mercaptoethanol, with or without 3.3 µM ATP), 5 µl of the diluted compounds were added to a final assay volume of 100 µl. Final concentrations were between 10 µM, and 0.3 nM in 0.25% DMSO. The assay was initiated by the addition of 10µl (30 ng) of KDR kinase domain.

The assay was incubated with test compound or vehicle alone with gentle agitation 20 at room temperature for 60 minutes. The wells were washed and phosphotyrosines (PY) were probed with an anti-phosphotyrosine (PY), mAb clone 4G10 (Upstate Biotechnology, Lake Placid, NY). PY/anti-PY complexes were detected with an anti-mouse IgG/HRP conjugate (Amersham International plc, Buckinghamshire, England). Phosphotyrosine was quantitated by incubating with 100 µl 3, 3', 5, 5' 25 tetramethylbenzidine solution (Kirkegaard and Perry, TMB Microwell 1 Component peroxidase substrate). Color development was arrested by the addition of 100 µl 1% HCl-based stop solution (Kirkegaard and Perry, TMB 1 Component Stop Solution).

Optical densities were determined spectrophotometrically at 450 nm in a 96-well 30 plate reader, SpectraMax 250 (Molecular Devices). Background (no ATP in assay) OD values were subtracted from all ODs and the percent inhibition was calculated according to the equation:

$$\begin{aligned} \text{\% Inhibition} &= \frac{(\text{OD(vehicle control)} - \text{OD(with compound)}) \times 100}{\text{OD(vehicle control)} - \text{OD(no ATP added)}} \end{aligned}$$

The IC₅₀ values were determined with a least squares analysis program using compound concentration versus percent inhibition. Compounds that have IC₅₀ < 100 nM in this assay include those of Examples 1, 2, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16 and 23.

5 Compounds that have IC₅₀ values between 100 nM and 1,000 nM include those of examples 8, 9 and 22. Those that have measured IC₅₀ values > 1,000 nM include those of examples 3, 17, 18 and 21.

Cell mechanistic assay-Inhibition of 3T3 KDR phosphorylation:

10 NIH3T3 cells expressing the full length KDR receptor were grown in DMEM (Life Technologies, Inc., Grand Island, NY) supplemented with 10% newborn calf serum, low glucose, 25 mM /L sodium pyruvate, pyridoxine hydrochloride and 0.2 mg/ ml of G418 (Life Technologies Inc., Grand Island, NY). The cells were maintained in collagen I-coated T75 flasks (Becton Dickinson Labware, Bedford, MA) in a humidified 5% CO₂ 15 atmosphere at 37°C.

Fifteen thousand cells were plated into each well of a collagen I-coated 96-well plate in the DMEM growth medium. Six hours later, the cells were washed and the medium was replaced with DMEM without serum. After overnight culture to quiesce the cells, the medium was replaced by Dulbecco's phosphate-buffered saline (Life 20 Technologies Inc., Grand Island, NY) with 0.1% bovine albumin (Sigma Chemical Co., St Louis, MO). After adding various concentrations (0-300 nM) of test compounds to the cells in 1% final concentration of DMSO, the cells were incubated at room temperature for 30 minutes. The cells were then treated with VEGF (30 ng / ml) for 10 minutes at room temperature. Following VEGF stimulation, the buffer was removed and the cells 25 were lysed by addition of 150 µl of extraction buffer (50 mM Tris, pH 7.8, supplemented with 10% glycerol, 50 mM BGP, 2 mM EDTA, 10 mM NaF, 0.5 mM NaVO₄, and 0.3% TX-100) at 4°C for 30 minutes.

To assess receptor phosphorylation, 100 microliters of each cell lysate was added to the wells of an ELISA plate precoated with 300 ng of antibody C20 (Santa Cruz 30 Biotechnology, Inc., Santa Cruz , CA). Following a 60-minute incubation, the plate was washed and bound KDR was probed for phosphotyrosine using an anti-phosphotyrosine mAb clone 4G10 (Upstate Biotechnology, Lake Placid, NY). The plate was washed and wells were incubated with anti-mouse IgG/HRP conjugate (Amersham International plc, Buckinghamshire, England) for 60 minutes. Wells were washed and phosphotyrosine was

quantitated by addition of 100 μ l per well of 3,3',5,5' tetramethylbenzidine (Kirkegaard and Perry, TMB Microwell 1 Component peroxidase substrate) solution. Color development was arrested by the addition of 100 μ l 1% HCl based stop solution (Kirkegaard and Perry, TMB 1 Component Stop Solution).

5 Optical densities (OD) were determined spectrophotometrically at 450 nm in a 96-well plate reader (SpectraMax 250, Molecular Devices). Background (no VEGF added) OD values were subtracted from all ODs and percent inhibition was calculated according to the equation:

10
$$\frac{\% \text{ Inhibition} = (\text{OD(VEGF control)} - \text{OD(with test compound)}) \times 100}{\text{OD(VEGF control)} - \text{OD(no VEGF added)}}$$

IC₅₀s were determined with a least squares analysis program using compound concentration versus percent inhibition. Compounds that have IC₅₀ < 20 nM in this assay 15 include those of Examples 2, 6, 7, 11, 15 and 16. Compounds that have IC₅₀ values between 20 nM and 50 nM include those of examples 1, 4, 5, 8, 10, 12, 13 and 14. Those that have measured IC₅₀ values > 50 nM include those of examples 9 and 21.

Matrigel® Angiogenesis Model:

20 **Preparation of Matrigel Plugs and *in vivo* Phase:** Matrigel® (Collaborative Biomedical Products, Bedford, MA) is a basement membrane extract from a murine tumor composed primarily of laminin, collagen IV and heparan sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C.

25 Liquid Matrigel at 4° C was mixed with SK-MEL2 human tumor cells that were transfected with a plasmid containing the murine VEGF gene with a selectable marker. Tumor cells were grown *in vitro* under selection and cells were mixed with cold liquid Matrigel at a ratio of 2 X 10⁶ per 0.5 ml. One half milliliter was implanted subcutaneously near the abdominal midline using a 25 gauge needle. Test compounds 30 were dosed as solutions in Ethanol/ Cremaphor-EL/saline (12.5%:12.5%:75%) at 30, 100, and 300 mg/kg po once daily starting on the day of implantation. Mice were euthanized 12 days post-implantation and the Matrigel pellets were harvested for analysis of hemoglobin content.

Hemoglobin Assay: The Matrigel pellets were placed in 4 volumes (w/v) of 4° C Lysis Buffer (20mM Tris pH 7.5, 1mM EGTA, 1mM EDTA, 1% Triton X-100 [EM

Science, Gibbstown, N.J.], and complete, EDTA-free protease inhibitor cocktail [Mannheim, Germany]), and homogenized at 4°C. Homogenates were incubated on ice for 30 minutes with shaking and centrifuged at 14K x g for 30 minutes at 4° C. Supernatants were transferred to chilled microfuge tubes and stored at 4° C for 5 hemoglobin assay.

Mouse hemoglobin (Sigma Chemical Co., St. Louis, MO) was suspended in autoclaved water (BioWhittaker, Inc, Walkersville, MD.) at 5 mg/ ml. A standard curve was generated from 500 micrograms/ml to 30 micrograms/ml in Lysis Buffer (see above). Standard curve and lysate samples were added at 5 microliters /well in duplicate to a 10 polystyrene 96-well plate. Using the Sigma Plasma Hemoglobin Kit (Sigma Chemical Co., St. Louis, MO), TMB substrate was reconstituted in 50 mls room temperature acetic acid solution. One hundred microliters of substrate was added to each well, followed by 100 microliters /well of Hydrogen Peroxide Solution at room temperature. The plate was incubated at room temperature for 10 minutes.

15 Optical densities were determined spectrophotometrically at 600 nm in a 96-well plate reader, SpectraMax 250 Microplate Spectrophotometer System (Molecular Devices, Sunnyvale, CA). Background Lysis Buffer readings were subtracted from all wells.

Total sample hemoglobin content was calculated according to the following equation:

20

$$\text{Total Hemoglobin} = (\text{Sample Lysate Volume}) \times (\text{Hemoglobin Concentration})$$

25 The average Total Hemoglobin of Matrigel samples without cells was subtracted from each Total Hemoglobin Matrigel sample with cells. Percent inhibition was calculated according to the following equation:

$$\text{% Inhibition} = \frac{(\text{Average Total Hemoglobin Drug-Treated Tumor Lysates}) \times 100}{(\text{Average Total Hemoglobin Non-Treated Tumor Lysates})}$$

30


Both examples 1 and 2 showed significant activity in this assay at 30, 100 and 300 mg/kg po sid with > 50% inhibition of total hemoglobin content of the Matrigel samples from the dosed animals vs. those from vehicle control animals.

Other embodiments of the invention will be apparent to the skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

WE CLAIM:

1. A compound having the generalized structural formula


5



wherein


 R^1 and R^2 :

10 i) independently represent H or lower alkyl;
 ii) together form a bridge of structure




wherein binding is achieved via the terminal carbon atoms;

iii) together form a bridge of structure



15 wherein binding is achieved via the terminal carbon atoms; or

iv) together form a bridge of structure



wherein one or two ring members T^1 are N and the others are CH, and binding is achieved via the terminal atoms; and

20 wherein

m is 0 or an integer 1 - 4; and

G^1 is a substituent independently selected from the group consisting of

25 • $-N(R^6)_2$;
 • $-NR^3COR^6$;

- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- 5 • lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- 10 • N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- 15 • phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- 20 • N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- 25 • phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- 30 • halogenated lower alkoxy;
- halogenated lower alkylthio;

- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- 5 • -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- 10 • guanidino;
- sulfo;
- -B(OH)2;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- 15 • optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- 20 • -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -CHO;
- -OCON(R⁶)₂;
- 25 • -NR³CO₂R⁶;
- -NR³CON(R⁶)₂

R³ is H or lower alkyl;

30 R⁶ is independently selected from the group consisting of

- H;
- alkyl;

- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

R^4 is H, halogen, or lower alkyl;

5

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NH;

10 Y is selected from the group consisting of

- $-(CR^4_2)_n-S(O)_p-(5\text{-membered heteroaryl})-(CR^4_2)_s-$;
- $-(CR^4_2)_n-C(G^2)(R^4)-(CR^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

15 G^2 is selected from the group consisting of $-CN$, $-CO_2R^3$, $-CON(R^6)_2$, and
 $-CH_2N(R^6)_2$;

- $-O-CH_2-$;
- $-S(O)-$;
- $-S(O)_2-$;
- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;
- $-CH_2S(O)-$; and
- $-CH_2S(O)_2-$

25

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

30 a) the total number of N atoms in the ring containing A , B , D , E , and L is 1, 2, or 3; and

b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

G^3 is selected from the group consisting of

- lower alkyl;
- 5 • $-NR^3COR^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- $-OR^6$;
- $-SR^6$;
- 10 • $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- 15 • $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- $-CN$;
- 20 • optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocycl;
- optionally substituted partially unsaturated heterocycl;
- optionally substituted heteroarylalkyl;
- 25 • optionally substituted heteroaryloxy;
- $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$ (optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- 30 • $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

5

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and G^4 moieties are selected from the group consisting of

10

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;

15

- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;

20

- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;

25

- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;

30


- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;

- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- 5 • -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- 10 • -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- 15 • -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- 20 • -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- 25 • -OCO₂R³;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- 30 • -S(O)_p(optionally substituted heteroarylalkyl);
- -CHO;

- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$
- fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

5

a)




wherein

10

each T^2 independently represents N, CH, or CG^4 ; T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; andbinding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

15

each T^2 independently represents N, CH, or CG^4 ;with the proviso that a maximum of two bridge atoms T^2 may be N ;
andbinding to ring J is achieved via terminal atoms T^2 ; and

c)



20

wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; andbinding to ring J is achieved via terminal atoms T^4 or T^5 ;

25

with the provisos that:

- i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $\text{C}(\text{R}^4)_2$;
- ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;


5 and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a N-containing heterocycle of 5 – 7 ring atoms; and

10 - when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoyl amino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CHO, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

15 or a pharmaceutically acceptable salt or prodrug thereof.


20 2. A compound having the generalized structural formula



wherein

R¹ and R²:


i) together form a bridge of structure



25

wherein binding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and binding is achieved via the terminal atoms; and

5

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

10

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;

20

25

30

- $-\text{CON}(\text{R}^6)_2$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted heteroarylalkyl;
- 5 • optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);

10 **R^3 is H or lower alkyl;**

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- 15 • optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

20 **Y is selected from the group consisting of**

- $-(\text{CH}_2)_n-\text{S}(\text{O})_p-(5\text{-membered heteroaryl})-(\text{CH}_2)_s-$;
- $-(\text{CH}_2)_n-\text{C}(\text{G}^2)(\text{H})-(\text{CH}_2)_s-$;

wherein

n and s are each independently 0 or 1; and

25 **G^2 is selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, and**
 $-\text{CH}_2\text{N}(\text{R}^6)_2$;

- $-\text{O}-\text{CH}_2-$;
- $-\text{S}(\text{O})-$;
- $-\text{S}(\text{O})_2-$;
- 30 • $-\text{SCH}_2-$;
- $-\text{S}(\text{O})\text{CH}_2-$;
- $-\text{S}(\text{O})_2\text{CH}_2-$;

- $-\text{CH}_2\text{S}(\text{O})-$; and
- $-\text{CH}_2\text{S}(\text{O})_2-$

A and D independently represent N or CH;

5 L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
- b) when L represents CH, at least one of A and D is an N atom;

10 q is 0, 1, or 2;

G^3 is selected from the group consisting of

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;
- 15 • $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- $-\text{CO}_2\text{R}^6$;
- 20 • $-\text{CON}(\text{R}^6)_2$;
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;
- $-\text{CN}$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- 25 • optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);


30

q' represents the number of substituents G^4 on the phenyl ring and is 0, 1, 2, or 3;
and

G^4 moieties are selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- 5 • alkyl;
- halogen-substituted alkyl;
- hydroxy-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- 10 • amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- 15 • carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- 20 • $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- 25 • $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- 30 • $-NO_2$;
- $-CN$;

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- S(O)_p(optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:


5
a)

10

wherein

each T² independently represents N, CH, or CG⁴;T³ represents S, O, CHG⁴, CH₂, or NR³; andbinding to the phenyl ring is achieved via terminal atoms T² and T³;

b)



15

wherein


each T² independently represents N, CH, or CG⁴;with the proviso that a maximum of two bridge atoms T² may be N ;

and

20

binding to the phenyl ring is achieved via terminal atoms T²; and

c)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³;

25

and

binding to the phenyl ring is achieved via terminal atoms T⁵ ;

with the provisos that:

- i) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

5

and with the further provisos that:

10


- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, and cyano;

15

or a pharmaceutically acceptable salt or prodrug thereof.

20

3. A compound having the generalized structural formula




wherein

R^1 and R^2 :


25

i) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms, and any group G^1 is located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T^1 is N and the others are CH, and binding is achieved via the terminal atoms; and

5

wherein

m is 0 or an integer 1 – 2; and

G^1 is a substituent independently selected from the group consisting of

10

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- $-OR^6$ wherein R^6 represents lower alkyl;
- $-NO_2$;
- optionally substituted heteroaryloxy;
- optionally substituted heteroarylalkyloxy;

15

R^3 is H or lower alkyl;

20

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

25

p is 0 or 1;

Y is selected from the group consisting of

30

- $-S(O)_p-(5\text{-membered heteroaryl})-$;
- $-C(CN)(H)-$;
- $-O-CH_2-$;

- $-S(O)-$; and
- $-S(O)_2-$;

q is 0 or 1;

5

G^3 is selected from the group consisting of

- lower alkyl;
- $-NR^3COR^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;

10

q' represents the number of substituents G^4 on the phenyl ring and is 0, 1, 2, or 3;
and

15

G^4 moieties are selected from the group consisting of

- $-N(R^6)_2$;
- halogen;
- lower alkyl;
- halogen-substituted lower alkyl;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;

20

- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;


25

- $-CON(R^6)_2$;
- $-CH_2OR^3$;
- $-NO_2$;

30

- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- 5 • optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




10

wherein

each T² independently represents N, CH, or CG⁴;T³ represents S, O, CHG⁴, CH₂, or NR³; andbinding to the phenyl ring is achieved via terminal atoms T² and T³;

15

b)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³;

and

binding to the phenyl ring is achieved via terminal atoms T⁵;

20

with the provisos that:

i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; andii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

25

and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N-atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 6 ring atoms; and

5

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, $-CO_2R^3$, $-CON(R^6)_2$, nitro, and cyano;

10

or a pharmaceutically acceptable salt or prodrug thereof.


4. A pharmaceutical composition comprising a compound of claim 1 and a 15 pharmaceutically acceptable carrier.

5. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said

mammal an amount of a compound of claim 1 which is effective to treat said condition.

6. The method of claim 5, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder 25 associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

7. A compound having the generalized structural formula




30

wherein

R^1 and R^2 :

- i) - independently represent H or lower alkyl;
- ii) together form a bridge of structure


5



wherein binding is achieved via the terminal carbon atoms;


- iii) together form a bridge of structure

10



wherein binding is achieved via the terminal carbon atoms; or

- iv) together form a bridge of structure



wherein one or two ring members T^1 are N and the others are CH, and binding is achieved via the terminal atoms; and

wherein

15

m is 0 or an integer 1 – 4; and

G^1 is a substituent independently selected from the group consisting of

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;

- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- 5 • lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- 10 • N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- 15 • lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- 20 • -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- 25 • -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- 30 • -CN;
- amidino;

- guanidino;
- sulfo;
- -B(OH)2 ;
- optionally substituted aryl;
- 5 • optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;
- optionally substituted heteroarylalkyl;
- 10 • optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -CHO;
- 15 • -OCON(R⁶)₂ ;
- -NR³CO₂R⁶ ;
- -NR³CON(R⁶)₂

R³ is H or lower alkyl;

20 R⁶ is independently selected from the group consisting of

- H;
- alkyl;
- optionally substituted aryl;
- 25 • optionally substituted aryl lower alkyl; and

R⁴ is H, halogen, or lower alkyl;

p is 0, 1, or 2;

30 X is selected from the group consisting of O, S, and NH;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- -CH₂-O-;
- -CH₂-S-;
- 5 • -CH₂-NH-;
- -O-;
- -S-;
- -NH-;
- -(CR⁴)_n-S(O)_p-(5-membered heteroaryl)-(CR⁴)_s-;
- 10 • -(CR⁴)_n-C(G²)(R⁴)-(CR⁴)_s-;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and -CH₂N(R⁶)₂;

- 15 • -O-CH₂-;
- -S(O)-;
- -S(O)₂-;
- -SCH₂-;
- -S(O)CH₂-;
- 20 • -S(O)₂CH₂-;
- -CH₂S(O)-; and
- -CH₂S(O)₂-

A and D independently represent N or CH;

25 B and E independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and
- 30 b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

G^3 is selected from the group consisting of

- $-NR^3COR^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- 5 • $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-OCOR^6$;
- 10 • $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- 15 • $-NO_2$;
- $-CN$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocycll;
- 20 • optionally substituted partially unsaturated heterocycll;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- 25 • $-S(O)_p$ (optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$;
- $-NR^3CON(R^6)_2$;

30 J is a ring selected from the group consisting of

- aryl;

- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

5 G^4 moieties are selected from the group consisting of


- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- 10 • cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- 15 • N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- 20 • carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- 25 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- 30 • carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;

- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- 5 • halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- 10 • -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- 15 • -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- 20 • optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;
- 25 • optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- 30 • -CHO;
- -OCON(R⁶)₂;

- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$
- fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

5

a)




wherein

each T^2 independently represents N, CH, or CG^4 ; T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; and

10

binding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

each T^2 independently represents N, CH, or CG^4 ;

15

with the proviso that a maximum of two bridge atoms T^2 may be N ;
andbinding to ring J is achieved via terminal atoms T^2 ; and

c)



20

wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; andbinding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

25

i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $\text{C}(\text{R}^4)_2$;ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and

iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;


5 and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a N-containing heterocycle of 5 – 7 ring atoms; and

10 - when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoyleamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CHO, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

15 or a pharmaceutically acceptable salt or prodrug thereof.


20 8. A compound having the generalized structural formula



wherein

R¹ and R²:


i) together form a bridge of structure



25

wherein binding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T^1 is N and the others are CH, and binding is achieved via the terminal atoms; and

5

wherein

m is 0 or an integer 1 – 2; and

G^1 is a substituent independently selected from the group consisting of

10

- $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;

20

25

30

- $-\text{CON}(\text{R}^6)_2$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted heteroarylalkyl;
- 5 • optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);

10 R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- 15 • optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

20 Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- $-\text{CH}_2-\text{O}-$;
- $-\text{CH}_2-\text{S}-$;
- $-\text{CH}_2-\text{NH}-$;
- 25 • $-\text{O}-$;
- $-\text{S}-$;
- $-\text{NH}-$;
- $-(\text{CH}_2)_n-\text{S}(\text{O})_p-(5\text{-membered heteroaryl})-(\text{CH}_2)_s-$;
- $-(\text{CH}_2)_n-\text{C}(\text{G}^2)(\text{H})-(\text{CH}_2)_s-$;

30 wherein

n and s are each independently 0 or 1; and

G^2 is selected from the group consisting of $-CN$, $-CO_2R^3$, $-CON(R^6)_2$, and $-CH_2N(R^6)_2$;

- $-O-CH_2-$;
- $-S(O)-$;
- 5 • $-S(O)_2-$;
- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;
- $-CH_2S(O)-$; and
- 10 • $-CH_2S(O)_2-$

A and D independently represent N or CH;

L represents N or CH;

with the provisos that

15 a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
 b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

20 G^3 is selected from the group consisting of

- $-NR^3COR^6$;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- 25 • $-S(O)_2R^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-CN$;
- 30 • optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heteroarylalkyl;

- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);

5


q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;
and

G⁴ moieties are selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- halogen-substituted alkyl;
- hydroxy-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoyl amino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;

- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- 5 • -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- 10 • optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




15

wherein

each T² independently represents N, CH, or CG⁴;T³ represents S, O, CHG⁴, C(H)₂, or NR³; andbinding to the phenyl ring is achieved via terminal atoms T² and T³;

20

b)




wherein

each T² independently represents N, CH, or CG⁴;with the proviso that a maximum of two bridge atoms T² may be N;

and

binding to the phenyl ring is achieved via terminal atoms T²; and

c)



wherein

each T^5 , and T^6 independently represents O, S, CHG^4 , $C(H)_2$, or NR^3 ;
and

binding to the phenyl ring is achieved via terminal atoms T^5 ;

5

with the provisos that:

- i) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

10


and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, and cyano;

20 or a pharmaceutically acceptable salt or prodrug thereof.

25


9. A compound having the generalized structural formula



wherein


R¹ and R²:

i) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms, and any group G¹ is
5 located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and binding is
achieved via the terminal atoms; and

10 wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- 15 • -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- -OR⁶ wherein R⁶ represents lower alkyl;
- -NO₂;
- 20 • optionally substituted heteroaryloxy;
- optionally substituted heteroarylalkyloxy;

R³ is H or lower alkyl;

25 R⁶ is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

30

p is 0 or 1;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH;
- 5 • -CH₂-O- ;
- -S- ;
- -NH- ;
- -S(O)_p-(5-membered heteroaryl)-;
- -C(CN)(H)- ;
- 10 • -O-CH₂- ;
- -S(O)- ; and
- -S(O)₂- ;

q is 0 or 1;

15

G³ is selected from the group consisting of

- -NR³COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂ ;
- 20 • -S(O)₂N(R⁶)₂ ;

q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;


and

G⁴ moieties are selected from the group consisting of

- 25 • -N(R⁶)₂ ;
- halogen;
- lower alkyl;
- halogen-substituted lower alkyl;
- -OR⁶;
- 30 • -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;

- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T² independently represents N, CH, or CG⁴;

T³ represents S, O, CHG⁴, CH₂, or NR³; and

binding to the phenyl ring is achieved via terminal atoms T² and T³;

b)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³;

and

binding to the phenyl ring is achieved via terminal atoms T⁵;

with the provisos that:

- i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

5

and with the further provisos that:

10 - in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a N-containing heterocycle of 5 – 6 ring atoms; and

15 - when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, -CO₂R³, -CON(R⁶)₂, nitro, and cyano;

20 or a pharmaceutically acceptable salt or prodrug thereof.

20

10. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.


25

11. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said mammal an amount of a compound of claim 7 which is effective to treat said condition.

30

12. The method of claim 11, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.


13. A compound having the generalized structural formula




wherein

R¹ and R²:


5 i) independently represent H or lower alkyl;
 ii) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms;
 iii) together form a bridge of structure



10 wherein binding is achieved via the terminal carbon atoms; or
 iv) together form a bridge of structure



wherein one or two ring members T¹ are N and the others are CH, and binding
 15 is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 - 4; and

20 G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;

25

- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- 5 • N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- 10 • carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- 15 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- 20 • carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- 25 • -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- 30 • -OCOR⁶;
- -COR⁶;

- $-\text{CO}_2\text{R}^6$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{NO}_2$;
- 5 • $-\text{CN}$;
- amidino;
- guanidino;
- sulfo;
- $-\text{B}(\text{OH})_2$;
- 10 • optionally substituted aryl;
- optionally substituted heteroaryl;
 - optionally substituted saturated heterocyclil;
 - optionally substituted partially unsaturated heterocyclil;
- $-\text{OCO}_2\text{R}^3$;
- 15 • optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- 20 • $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$

25 R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- alkyl;
- 30 • optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

5 X is selected from the group consisting of O, S, and NH;

Y is selected from the group consisting of

• lower alkylene, optionally substituted by OH or OAcyl;

• $-CH_2-O-$;

10 • $-CH_2-S-$;

• $-CH_2-NH-$;

• $-O-$;

• $-S-$;

• $-NH-$;

15 • $-(CR^4_2)_n-S(O)_p-(5\text{-membered heteroaryl})-(CR^4_2)_s-$;

• $-(CR^4_2)_n-C(G^2)(R^4)-(CR^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and

20 $-CH_2N(R^6)_2$;

• $-O-CH_2-$;

• $-S(O)-$;

• $-S(O)_2-$;

• $-SCH_2-$;

25 • $-S(O)CH_2-$;

• $-S(O)_2CH_2-$;

• $-CH_2S(O)-$; and

• $-CH_2S(O)_2-$

30 A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and
- b) when L represents CH, at least one of A and D is an N atom;

5 q is 0, 1, or 2;

G^3 is selected from the group consisting of

- lower alkyl;
- $-NR^3COR^6$;
- 10 • carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- 15 • $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- 20 • $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- $-CN$;
- optionally substituted aryl;
- 25 • optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- 30 • $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$ (optionally substituted heteroarylalkyl);

- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$;

5 J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

10 q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and G^4 moieties are selected from the group consisting of

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);


15 • optionally substituted heteroarylalkyloxy;

- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;

20 • $-\text{NR}^3\text{CON}(\text{R}^6)_2$

- fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)




25 wherein

each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; and

binding to ring J is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

each T^2 independently represents N, CH, or CG^4 ;

5

with the proviso that a maximum of two bridge atoms T^2 may be N ;
andbinding to ring J is achieved via terminal atoms T^2 ; and

c)



10

wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $C(R^4)_2$, or NR^3 ; andbinding to ring J is achieved via terminal atoms T^4 or T^5 ;

with the provisos that:

15

i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; andiii) in a bridge comprising T^5 and T^6 atoms, when one T^5 is O, the other T^5 is S, CR^4G^4 , $C(R^4)_2$ or NR^3 ;iv) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

20

25

and with the further provisos that:


- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-\text{CO}_2\text{R}^3$, $-\text{CHO}$, $-\text{CH}_2\text{OR}^3$, $-\text{OCO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, $-\text{OCO N}(\text{R}^6)_2$, $-\text{NR}^3\text{CON}(\text{R}^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.

10

14. A compound having the generalized structural formula




wherein

R^1 and R^2 :


15

i) together form a bridge of structure



wherein binding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



20

wherein one of the ring members T^1 is N and the others are CH, and binding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

25

G^1 is a substituent independently selected from the group consisting of

- $-\text{N}(\text{R}^6)_2$;

- $-\text{NR}^3\text{COR}^6$;
- halogen;
- alkyl;
- amino-substituted alkylamino;
- 5 • N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- 10 • lower alkoxycarbonyl-substituted alkylamino;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- 15 • halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-\text{OCOR}^6$;
- $-\text{COR}^6$;
- 20 • $-\text{CO}_2\text{R}^6$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted heteroarylalkyl;
- 25 • optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);

30 R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- 5 • optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y is selected from the group consisting of

- 10 • lower alkylene, optionally substituted by OH or OAcyl;
- $-\text{CH}_2-\text{O}-$;
- $-\text{CH}_2-\text{S}-$;
- $-\text{CH}_2-\text{NH}-$;
- $-\text{O}-$;
- 15 • $-\text{S}-$;
- $-\text{NH}-$;
- $-(\text{CH}_2)_n-\text{S}(\text{O})_p-(5\text{-membered heteroaryl})-(\text{CH}_2)_s-$;
- $-(\text{CH}_2)_n-\text{C}(\text{G}^2)(\text{H})-(\text{CH}_2)_s-$;

wherein

20 n and s are each independently 0 or 1; and

G^2 is selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, and
 $-\text{CH}_2\text{N}(\text{R}^6)_2$;

- $-\text{O}-\text{CH}_2-$;
- $-\text{S}(\text{O})-$;
- 25 • $-\text{S}(\text{O})_2-$;
- $-\text{SCH}_2-$;
- $-\text{S}(\text{O})\text{CH}_2-$;
- $-\text{S}(\text{O})_2\text{CH}_2-$;
- $-\text{CH}_2\text{S}(\text{O})-$; and
- 30 • $-\text{CH}_2\text{S}(\text{O})_2-$

A and D independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
- b) when L represents CH, at least one of A and D is an N atom;

5

q is 0, 1, or 2;

G³ is selected from the group consisting of

- lower alkyl;
- 10 • -NR³COR⁶;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- 15 • -CO₂R⁶;
- -CON(R⁶)₂;
- -S(O)₂N(R⁶)₂;
- -CN;
- optionally substituted aryl;
- 20 • optionally substituted heteroaryl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- 25 • -S(O)_p(optionally substituted heteroarylalkyl);

q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;
and


G⁴ moieties are selected from the group consisting of

- 30 • optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);

- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$ (optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

5

a)




wherein

each T^2 independently represents N, CH, or CG^4 ; T^3 represents S, O, CHG^4 , $C(H)_2$, or NR^3 ; and

10

binding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

each T^2 independently represents N, CH, or CG^4 ;

15

with the proviso that a maximum of two bridge atoms T^2 may be N ;
andbinding to the phenyl ring is achieved via terminal atoms T^2 ; and

c)



20

wherein

each T^5 , and T^6 independently represents O, S, CHG^4 , CH_2 , or NR^3 ;

and

binding to the phenyl ring is achieved via terminal atoms T^5 ;

with the provisos that:

25

- a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- in a bridge comprising T^5 and T^6 atoms, when one T^5 is O, the other T^5 is S, CHG^4 , CH_2 or NR^3 ;

iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

5

and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing heterocycle of 5 – 7 ring atoms; and


10

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, and cyano;

15

or a pharmaceutically acceptable salt or prodrug thereof.


20 15. A compound having the generalized structural formula



wherein

R^1 and R^2 :


i) together form a bridge of structure



25

wherein binding is achieved via the terminal carbon atoms, and any group G^1 is located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T^1 is N and the others are CH, and binding is achieved via the terminal atoms; and

5 wherein

m is 0 or an integer 1 – 2; and

G^1 is a substituent independently selected from the group consisting of

- 10 • $-N(R^6)_2$;
- $-NR^3COR^6$;
- halogen;
- $-OR^6$ wherein R^6 represents lower alkyl;
- $-NO_2$;
- 15 • optionally substituted heteroaryloxy;
- optionally substituted heteroarylalkyloxy;

R^3 is H or lower alkyl;

20 R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

25

p is 0 or 1;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH;
- 30 • $-CH_2-O-$;
- $-S-$;

- -NH-;
- -S(O)_p-(5-membered heteroaryl)-;
- -C(CN)(H)-;
- -O-CH₂-;
- 5 • -S(O)-; and
- -S(O)₂-;

q is 0 or 1;

10

G³ is selected from the group consisting of

15

- lower alkyl;
- -NR³COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -S(O)₂N(R⁶)₂;

q' represents the number of substituents G⁴ on the phenyl ring, and is 0, 1, 2, or 3;
and


20

G⁴ moieties are selected from the group consisting of

25

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




30

wherein

each T² independently represents N, CH, or CG⁴;

T^3 represents S, O, CHG^4 , CH_2 , or NR^3 ; and
binding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

b)



5

wherein

each T^5 , and T^6 independently represents O, S, CHG^4 , CH_2 , or NR^3 ;
and

binding to the phenyl ring is achieved via terminal atoms T^5 ;
with the provisos that:

10 i) a bridge comprising T^5 and T^6 atoms may contain a maximum of
two heteroatoms O, S, or N; and
ii) in a bridge comprising T^5 and T^6 atoms, when one T^5 is O, the
other T^5 is S, CR^4G^4 , $C(R^4)_2$ or NR^3 ;
iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and
15 one T^6 group are O atoms, or two T^6 groups are O atoms, said O
atoms are separated by at least one carbon atom;

and with the further provisos that:

20 - in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same
N atom they may be linked by a bond, an O, an S, or NR^3 to form a N-containing
heterocycle of 5 – 6 ring atoms; and
25 - when an aryl, heteroaryl, or heterocycll ring is optionally substituted, that ring
may bear up to 2 substituents which are independently selected from the group
consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted
amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl,
hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated
lower alkylthio, $-CO_2R^3$, $-CON(R^6)_2$, nitro, and cyano;
30 or a pharmaceutically acceptable salt or prodrug thereof.

16. A pharmaceutical composition comprising a compound of claim 13 and a
pharmaceutically acceptable carrier.

17. A method of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to said mammal an amount of a compound of claim 13 which is effective to treat said condition.

5

18. The method of claim 17, wherein said condition is tumor growth; retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, and age-related macular degeneration; rheumatoid arthritis; psoriasis; or a 10 bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.

19. A compound selected from the group consisting of:

15

- a) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide;
- b) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide;
- c) 1-(4-chlorophenylamino)-4-(3-pyridylmethoxy)phthalazine;
- d) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid 20 methylamide;
- e) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide;
- f) 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid methylamide;

25

- g) 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid amide;
- h) 1-(4-chlorophenylamino)-4-[(2-phenyl-4-pyridyl)methyl]phthalazine;
- i) 1-[4-(4-pyridyloxy)phenylamino]-4-(4-pyridylmethyl)phthalazine;
- j) 1-(indan-5-ylamino)-4-(4-pyridylmethyl)phthalazine;

30

- k) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dihydrochloride;
- l) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dimethanesulfonate;

- m) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dihydrochloride;
- n) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dimethanesulfonate;
- 5 o) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide dihydrochloride;
- p) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide dimethanesulfonate;
- q) 1-(4-chlorophenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine;
- 10 r) 1-(4-isopropylphenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine;
- s) 1-(4-chlorophenylamino)-4-(4-pyridylsufonyl)phthalazine;
- t) 1-(4-chlorophenylamino)-4-(4-pyridylsufinyl)phthalazine;
- u) 1-(4-chlorophenylamino)-4-(4-pyridylmethoxy)pyridazine;
- 15 v) 1-(indan-5-ylamino)-4-(4-pyridylcyanomethyl)phthalazine; and
- w) 1-(benzothiazol-6-ylamino)-4-(4-pyridylcyanomethyl)phthalazine.

INTERNATIONAL SEARCH REPORT

Internati

Application No

PCT/US 00/21579

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 C07D401/06 C07D401/14 C07D417/14 A61K31/50
A61P9/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 35958 A (NOVARTIS) 20 August 1998 (1998-08-20) cited in the application claims; examples 48-51 ----	1-16
X	EP 0 722 936 A (EISAI) 24 July 1996 (1996-07-24) claims; examples 1-60, 68, 69, 79 & US 5 849 741 A (N. WATANABE) 15 December 1998 (1998-12-15) cited in the application ----	1-16
X		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 December 2000

Date of mailing of the international search report

27/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/21579

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 115, no. 28, 1991 Columbus, Ohio, US; abstract no. 256197s, page 869; XP002155239 cited in the application abstract & JP 03 106875 A (MORISHITA) 7 May 1991 (1991-05-07) ----	1-16
A	US 3 753 988 A (R.E. RODWAY ET AL.) 21 August 1973 (1973-08-21) cited in the application column 7 -column 9 -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati

Application No

PCT/US 00/21579

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9835958	A 20-08-1998	AU 6621898	A	08-09-1998
		BR 9807685	A	21-03-2000
		CN 1251097	T	19-04-2000
		CZ 9902853	A	17-11-1999
		EP 0970070	A	12-01-2000
		NO 993888	A	11-10-1999
		PL 335113	A	10-04-2000
		SK 109699	A	13-03-2000
		ZA 9801155	A	13-08-1998
EP 722936	A 24-07-1996	AU 705229	B	20-05-1999
		AU 3191995	A	07-03-1996
		FI 961510	A	29-05-1996
		KR 189865	B	01-06-1999
		NO 961397	A	06-06-1996
		NZ 290952	A	27-05-1998
		RU 2128175	C	27-03-1999
		US 5849741	A	15-12-1998
		CA 2173493	A	22-02-1996
		CN 1135210	A	06-11-1996
		HU 76067	A	30-06-1997
		WO 9605176	A	22-02-1996
		JP 8225541	A	03-09-1996
JP 03106875	A 07-05-1991	NONE		
US 3753988	A 21-08-1973	BE 749824	A	30-10-1970
		CH 523890	A	15-06-1972
		DE 2021195	A	12-11-1970
		FR 2043504	A	19-02-1971
		GB 1293565	A	18-10-1972
		IE 33777	B	30-10-1974
		JP 48039944	B	28-11-1973
		SE 376916	B	16-06-1975